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Abstract 
It has steadily become more recognized that even patients with progressively 
growing tumors are often mounting substantial immune responses against their 
tumor. The reasons why this immunity is unable to control the outgrowth of the 
tumor must be understood if we are to develop immunotherapeutic and 
preventative strategies against cancer. Experimental observations since the 1960s 
have suggested that cellular immunity generated against tumor antigens is 
protective, while some studies have led me to believe that humoral immunity may 
be associated with disease progression. This possibility has led me to test the 
hypothesis that the cause of immune failure is immune-deviation. 
The experimental system I chose employs the P815 mastocytoma and 
L5178Y lymphoma tumors, both of which are of DBA origin. I have demonstrated 
that primary resistance to tumors correlates with Th1 responses, while primary 
progressive tumor growth is associated with a mixed Th1/Th2 immune response 
generated against tumor antigens. Such correlates were defined directly by 
assessing tumor-dependent cytokine secretion by T cells, and indirectly by 
assessing the relative abundance of tumor-specific IgG2a and IgG1 antibodies by 
western blot and enzyme-linked immunoassays. Moreover, I have demonstrated, 
utilizing these assays, that low doses of gamma irradiation, which have previously 
been shown to induce immune-mediated regression of established tumors, is 
associated with a phenotypic ‘switch’ in the anti-tumor immune response from a 
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mixed Th1/Th2 to a predominant Th1 response. The simplicity and reliability of using 
IgG isotypes to indirectly assess the Th1/Th2 nature of the anti-tumor immune 
response gives me hope that this work, in the long run, will result in a new way of 
guiding immunotherapy to effectively treat cancer. 
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1 Introduction 
Immunity to tumors has been studied for well over a century. Tumor 
immunology was born out of the inherent optimism following the successes 
scientists had in developing vaccines to prevent devastating infectious diseases 
such as small pox and poliomyelitis.   Scientists such as Ehrlich thought that 
tumors, like infections, must occur at a fairly high frequency. He felt that the 
immune system must actively repress the growth of various neoplasias (Ehrlich 
1909).  More recently, Burnet and Thomas suggested that the immune system 
must possess an active mechanism to protect long-lived organisms from 
developing cancer (Burnet 1957; Thomas 1959). Using modern immunological 
techniques it has been clearly demonstrated that there are spontaneous anti-
tumor immune responses being generated in both animal models of and in human 
cancers (Boon, Cerottini et al. 1994; Boon, Coulie et al. 2006).  
1.1 Cellular Control of Neoplasia 
Theories of immunosurveillance envisage that there are several layers of 
defense to control against the outgrowth of neoplastic cells. This defense consists 
of cellular and acellular components of the innate and adaptive immune systems, 
functioning in a concerted manner to prevent the development of clinical disease. 
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Failure of the innate and adaptive immune system could result in disease 
progression. This introduction will focus mainly on a review of: i) the cellular 
components of innate and adaptive anti-tumor immunity, ii) the characterization 
of tumor associated antigens and iii) suppressor/regulatory cells thought to inhibit 
the generation of effective anti-tumor immunity.  
1.1.1 Innate Cellular Control of Neoplasia 
1.1.1.1 Intraepithelial Lymphocytes 
Intraepithelial lymphocytes (IEL) are defined as a unique group of 
lymphocytes that primarily survey the epithelial tissues for the presence of 
infection. In the mouse skin, the resident IEL are composed almost entirely of  T 
cells while in the gut, the population of IEL consists of roughly 50%  and 50%  
T cells (Asarnow, Goodman et al. 1989). Unlike classical  T cells,  T cells in the 
skin tend to have a more restricted TCR diversity (Shin, El-Diwany et al. 2005), 
while  T cells in the gut often have a much more diverse TCR repertoire (Cron, 
Gajewski et al. 1989).  T cells are capable of recognizing unprocessed antigens in 
an MHC-unrestricted manner (Chien, Jores et al. 1996), and some believe they 
primarily recognize endogenous proteins expressed on the surface of cells after 
infection or malignant transformation (Havran, Chien et al. 1991). Upon 
recognizing a neoplastic cell, γ/δ T cells have the capacity to induce strong 
cytotoxic effector activities using either death receptor/death ligand or cytolytic 
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granule pathways, each capable of inducing apoptotic killing of transformed cells, 
and to produce cytokines such as tumor necrosis factor-α (TNFα), and interferon-γ 
(INFγ) to promote inflammation (Hayday 2000; Girardi, Oppenheim et al. 2001).  
Since the skin contains cells with a great potential to undergo transformation that 
may lead to malignant growth, these γ/δ T cells residing in the epithelia may play a 
very important role in both identifying, and initiating the killing of transformed 
cells.   
1.1.1.2 Natural Killer Cells 
Natural Killer (NK) cells are a unique population that was first identified for 
their ability to kill target cells against which they had not previously been primed. 
In 1986, Kärre reported that NK cells could effectively lyse a tumor cell that did not 
express MHC class I on its surface (RMA-S), but was unable to lyse the same tumor 
line if it expressed class I MHC on its surface (RMA) (Cerwenka, Baron et al. 2001). 
This experimental observation led to the theory that NK cells survey the body for 
cells that no longer present class I restricted antigens to the immune system, a 
surveillance that can lead to killing of the recognized cell. This idea became dogma 
until it was discovered that NK cells are able to reject class I bearing target cells 
provided that the target cells bore ligands recognized by activating receptors of the 
NK cell (Lanier, Corliss et al. 1997; Cerwenka, Baron et al. 2001; Diefenbach, Jensen 
et al. 2001). It has now been shown that NK cells express both inhibitory and 
activating receptors which coordinately regulate their activity.  
4 
 
NK cells have a large number of receptors, whose engagement alone, or in 
combination, account for their cytotoxicity. The natural cytotoxicity receptor (NCR) 
family is composed of three receptors, NKp30, NKp44 and NKp46 (Pessino, Sivori et 
al. 1998; Vitale, Bottino et al. 1998; Pende, Parolini et al. 1999), and their 
engagement accounts for an important part of NK cell natural cytotoxicity against 
multiple types of cancer. In addition to the NCR family of receptors, there are the 
Killing Inhibitory Receptors (KIRs), such as NKG2A, which forms a heterodimers 
with CD94. This heterodimers bind to non-classical MHC class I molecules called 
HLA-E (in humans) and Qa1 (in mice) and act to inhibit NK cytotoxicity (Diefenbach, 
Jamieson et al. 2000). Unlike traditional KIRs, NKG2D acts as an activating receptor, 
that when triggered induces the killing of the target cell. NKG2D forms a 
homodimeric receptor and binds one of several cell surface molecules that are only 
distantly related to MHC class I molecules (Raulet 2003). NKG2D receptor is 
expressed on the surface of almost all NK cells. Mouse CD8+ T cells gain expression 
of NKG2D after activation, while human CD8+ T cells constitutively express it on 
their surface. Roughly 25% of / T cells in the spleen, and 100% of / T cells in 
the mouse epidermis express the NKG2D receptor, and activated macrophages 
lose expression of the NKG2D receptor (Raulet 2003).  
In normal adult cells, these NKG2D ligands are absent, or present at very 
low concentrations, and are thought to be upregulated on the surface of ‘stressed’ 
cells, effectively alerting the innate immune system to cellular stresses including 
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transformation events (Nomura, Zou et al. 1996; Girardi, Oppenheim et al. 2001). 
Various NKG2D ligands have been detected on the surface of numerous murine 
and human tumor isolates (Groh, Rhinehart et al. 1999). Murine tumor lines that 
have been engineered to express high amounts of NKG2D ligands on their surface 
have failed to form a tumor in-vivo (Cerwenka, Baron et al. 2001; Diefenbach, 
Jensen et al. 2001). These studies, showing that ectopic high level expression of 
various NKG2D ligands results in rejection of primary tumors, contrasts with the 
observation that most human, and mouse tumor cell lines derived from 
progressively growing tumors, express these ligands on their surface. Why are NK 
and TCR+ T cells unable to control the outgrowth of these transformed cells? It is 
possible that these ligands play no role in the in vivo rejection of endogenous 
tumors. It is also possible that these tumor cell lines/isolates may have been 
selected for variants that do not express the ligands at sufficient levels to result in 
their killing. Alternatively, endogenously growing tumors may directly suppress 
NKG2D-mediated killing (Groh, Wu et al. 2002).  
1.1.1.3 Natural Killer T cells 
Natural Killer T (NKT) cells were first identified as a unique subset of T cells 
sharing qualities commonly associated with traditional NK cells. NKT cells express 
the NK1.1 (CD161c) marker, usually attributed to NK cells, however NKT cells also 
express a highly conserved /β T cell receptor (Makino, Kanno et al. 1995). NKT 
cells can recognize lipid antigens in the context of the CD1d molecule (Kawano, Cui 
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et al. 1997). Until recently, the CD1d-restricted ligand to which NKT cells were 
capable of responding was unknown. Most early studies utilized a pharmacological 
ligand capable of polyconally activating of NKT cells. Alpha-galactosyl ceramide (-
GalCer) is a lipid from a marine sponge that was first isolated based upon its ability 
to prevent tumor metastasis of the B16 tumor to the liver of mice (Kobayashi, 
Motoki et al. 1995). It was later demonstrated that this activity was due to CD1d-
mediated presentation of this lipid antigen to NKT cells expressing the invariant 
V14 T cell receptor which have become known as invariant natural killer T cells 
(iNKT) (Kawano, Cui et al. 1997). The natural ligands recognized by the iNKT cells 
remained elusive until very recently. Mycobacterial phosphatidylinositol 
mannoside (Fischer, Scotet et al. 2004), and mycobacterial phosphoethanolamide 
(Rauch, Gumperz et al. 2003) have been identified as exogenous antigens 
recognized by iNKT cells. The endogenous lipid isoglobotrihexosylceramide (iGb3) 
is recognized by both human and mouse iNKT cells. Not only are iNKT cells able to 
respond to iGb3 in the context of the CD1d molecule, but gene knockout mice that 
do not produce iGb3 also fail to generate iNKT cells. This strongly suggests that 
iGb3 is required for iNKT cell selection and/or maintenance in the periphery of 
mice (Laduron, Deplus et al. 2004) 
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1.1.1.4 NKT cells and tumor immunity 
The in-vivo function of NKT cells is not well understood, and there is some 
debate as to whether they act simply as immunomodulatory cells or if they have 
any role in host-defense against tumors and microbial infections. The idea that 
they act against tumors and microbial infections is based upon the observation 
that one can induce iNKT cells to secrete INF in a CD1d-dependent manner by 
culturing iNKT cells either with dendritic cells (DC) pulsed with Salmonella 
typimurium extract or with DCs and high levels of IL-12. These observations suggest 
DCs can present both exogenous and endogenously derived ligands recognizable 
by iNKT cells (Mattner, Debord et al. 2005).  At present, it is hypothesized that NKT 
cells may have no direct effector function with regards to tumor immunity, but 
rather may have a regulatory function by secreting INF or IL-4 and IL-13 in 
response to tumor antigens presented in the context of the CD1d molecule 
(Moodycliffe, Nghiem et al. 2000; Terabe, Matsui et al. 2000). 
1.2 Adaptive immune responses 
1.2.1 Generating Protective Anti-Tumor Immune Responses 
The ability to exploit the immune system to treat cancer has been a tantalizing, yet 
unrealized, goal of immunologists for well over a century. This apparent failure is 
despite strong evidence, in animal models, of the immune system’s ability to 
mount an effective anti-tumor immune response.  
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In the 1950s, with the availability of truely syngeneic strains of mice, 
contemporary immunologists began their study of the generation of anti-tumor 
immunity. The relative ease by which one could render mice resistant to a normally 
lethal dose of a syngeneic tumor led to great optimism that one could exploit the 
immune system to treat human cancers. Vaccination strategies such as excision 
priming (Foley 1953; Klein 1959), the administration of sub-tumorogenic doses of 
replicating tumor cells (Klein, Sjogren et al. 1960), or repeated immunization with 
heavily irradiated tumor cells (Revesz 1960) rendered mice resistant to a tumor 
challenge known to be lethal in naïve animals.  The protection generated by these 
various treatments was stable, and specific for the selecting tumor (Klein, Sjogren 
et al. 1960), and could be transferred to a naïve mouse by transferring T cells 
(Mikulska, Smith et al. 1966). A determination of the mechanisms by which T cells 
are capable of controlling the outgrowth of these neoplastic cells have been the 
basis of many experimental studies.  
1.2.2 CD4 and CD8 T cell responses against cancer 
Today, we recognize that CD4+ and CD8+ T cells are indispensable components 
of the adaptive immune system. T cells expressing the CD4+ marker recognize 
antigen presented by MHC class II molecules expressed by professional antigen 
presenting cells (APC) such as dendritic cells, macrophages and B cells. In contrast, 
CD8+ T cells recognize antigen presented by MHC class I molecules. Unlike class II, 
class I MHC is expressed by the vast majority of nucleated cells, allowing CD8+ T 
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cells to survey the body for virally infected or transformed cells (Abbas and 
Lichtman 2000). In addition to recognizing antigen in the context of different MHC 
molecules, CD4+ and CD8+ T cells have different biological functions. 
For the most part, CD4+ T cells act as helper cells, aiding in the activation, and 
promotion, of either humoral or cell mediated immunity. There are different 
theories which attempt to define the mechanisms by which naïve CD4+ T cells are 
activated in response to antigen (Janeway 1989; Matzinger 1994; Bretscher 1999). 
A review of these various theories of the activation requirements of naïve CD4+ T 
cells is beyond the scope of this introduction. Once activated, these effector CD4+ 
T cells can be divided into at least two populations, based upon their cytokine 
profiles (Mosmann and Coffman 1989). Cells of Th1 type secrete proinflammatory 
cytokines such as INFγ (Mosmann and Coffman 1989), and promote the activation 
of cell mediated immunity which includes cytotoxic T cells (Janssen, Lemmens et al. 
2003), macrophages and NK cells (Hoebe, Janssen et al. 2004). These cell types are 
thought to be more effective at containing the outgrowth of intracellular 
organisms and tumors (Bretscher, Hamilton et al. 2002). Cells of Th2 type secrete 
cytokines such as IL-4 and IL-5 in response to antigen (Mosmann and Coffman 
1989; Swain, Weinberg et al. 1990), and promote humoral responses. Such Th2 
responses are effective at containing extracellular bacteria and parasites (Abbas 
and Lichtman 2000). Although these two CD4+ T cell subsets are most often 
distinguished based upon the cytokines they produce, it has been shown in a 
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number of experimental systems that one can infer the Th1/Th2 nature of an 
ongoing immune response based upon the relative predominance of antigen-
specific Ig isotypes. In mice, it has been shown that exclusive Th1 responses 
correlate with no antibody production. Predominant Th1 responses correlate with 
the production of IgG2a antibody, Th1/Th2 mixed responses correlate with 
production of both IgG2a and IgG1 antibodies while a polarized Th2 response is 
associated with a predominance of IgG1 and IgE antibodies produced in response 
to antigen (Pond, Wassom et al. 1989; Menon and Bretscher 1996; Power, Wei et 
al. 1998). As the Th1 and Th2 nature of the immune response can have profound 
impacts on the outcome of various microbial infections, it is very important to 
understand the nature of the decision criterion controlling the Th1/Th2 phenotype 
of the response.   
Several theories attempt to explain what determines the Th1/Th2 nature of an 
immune response (Constant and Bottomly 1997; Kalinski, Hilkens et al. 1999; 
Rissoan, Soumelis et al. 1999; Mazzoni and Segal 2004). Many studies in Peter 
Bretscher’s laboratory assess a possible role for T cell cooperation in determining 
the phenotype of the CD4+ T cell response. This long standing theory proposes that 
the antigen-mediated cooperation of antigen-specific CD4+ T cells is needed to 
generate immune responses. Known as the threshold hypothesis, it suggests that 
low levels of CD4+ T cell cooperation preferentially lead to Th1, while high levels of 
cooperation lead to Th2 immune responses (Bretscher 1979; Tucker and Bretscher 
11 
 
1982; Bretscher 1983; Bretscher 1986; Ismail and Bretscher 1999; Ismail and 
Bretscher 2001; Ismail, Basten et al. 2005). Recently, experimental evidence has 
provided very direct support for this long standing proposition. K.K. McKinstry, a 
former graduate student in Peter Bretscher’s laboratory provided strong evidence 
that CD4+ T cells can cooperate in the generation of immune responses to linked 
antigens, and the degree to which the CD4+ T cells are capable of cooperating 
dictates the Th1/Th2 nature of the immune response (Mckinstry 2005). 
In this study, McKinstry transferred a standard number of normal spleen cells 
into lethally irradiated recipients, and gave an amount of OVA-conjucated 
xenogeneic red blood cells (XRBC) as antigen ten-fold lower than required to 
generate a specific immune response. By supplementing  this constant number of 
normal spleen cells with unprimed transgenic CD4+ T cells specific for OVA,  he was 
able to demonstrate that these transgenic cells were able to ‘help’ in the 
generation of immune responses against  the XRBC to which OVA had been 
chemically coupled. Furthermore, McKinstry was able to modulate the Th1/Th2 
nature of the anti-XRBC response by transferring different numbers of OVA-specific 
CD4+ T cells. Low numbers of transgenic T cells promoted a Th1 response, while 
higher numbers promoted a mixed Th1/Th2 immune response against the XRBC. 
Such modulation was only observed when the two antigens were physically linked 
(Mckinstry 2005). Such observations critically test the idea that the level of CD4+ T 
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cell cooperation influences the Th1/Th2 nature of an antigen-specific immune 
response.  
1.2.2.1 Activation of tumor-reactive CD8+ cytotoxic T cells    
It is readily accepted, in most instances, that CD8+ cytotoxic T cells (CTLs) are the 
major cell type involved in the direct killing of tumor cells; however, understanding 
the mechanism of how tumor-specific CTLs are activated can be conceptually 
challenging as many tumors do not express the costimulatory molecules required 
to fully activate naïve CTLs. Furthermore, as discussed above, many CTL responses 
require CD4+ T cell help (Mitchison 1983; Guerder and Matzinger 1992; Kirberg, 
Bruno et al. 1993; Janssen, Lemmens et al. 2003; Shedlock and Shen 2003; Sun and 
Bevan 2003). As most murine tumor cells do not express MHC class II molecules on 
their surface, the manner by which this help is delivered has been extensively 
studied.  Professional antigen presenting cells (APCs) have been known for their 
ability to take up, digest, and present exogenously proteins and present them to 
the immune system upon MHC class II molecules. This understanding had become 
dogma until a series of observations led Bevan to propose that professional APCs 
were capable of presenting exogenous proteins not only on MHC class II, but also 
on MHC class I molecules. This process has been called cross presentation (Huang, 
Golumbek et al. 1994; Bennett, Carbone et al. 1997; Albert, Sauter et al. 1998; 
Heath, Kurts et al. 1998), and has become key in our understanding of how 
precursor CTLs can become activated in response to neoplastic growth. Presently it 
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is believed that professional APCs will phagocytose, and present tumor-derived 
antigens on both MHC class I and II molecules. Effector CD4+ T helper cells, 
recognizing MHC class II restricted tumor antigens, are thought to then ‘license’ 
the APC by inducing the upregulation of costimulatory molecules required to fully 
activate naïve tumor-specific CD8+ T cells recognizing MHC class I restricted tumor 
antigens (Bennett, Carbone et al. 1998; Ridge, Di Rosa et al. 1998; Schoenberger, 
Toes et al. 1998). Once activated, tumor-specific CTLs can directly recognize, and 
kill transformed cells. 
1.2.2.2 Immune-mediated killing of tumor cells 
Cytotoxic T cells are the cells whose primary job is to identify, and specifically kill, 
virally infected or transformed cells (Harty, Tvinnereim et al. 2000). Upon a TCR-
mediated specific interaction with a target cell expressing a MHC class I restricted 
antigen, an activated CTL can utilize one of two distinct pathways to kill the target 
cell. The first method involves the directed release of granules towards the target 
cell. These granules contain various proteases along with perforin, which as the 
name suggests, acts similarly to the complement induced membrane attack 
complex, and forms pores in the membrane of the target cell (Young, Cohn et al. 
1986). The proteases released enter the target cell via the pores created by 
perforin, leading to a cascade of reactions resulting in the apoptotic death of the 
target cell (Smyth, O'Connor et al. 1996). The second method of CTL mediated 
killing involves an interaction between the Fas receptor and the Fas ligand. This 
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ligand on the CTL, upon interaction with the Fas receptor on the target cell, 
activates the caspase cascade in the target cell resulting in apoptosis (Nagata 
1996).  
In addition to the direct killing of tumor cells, CD8+ T cells also release 
cytokines such as interferon gamma (INFγ), which not only acts as an anti-
proliferative agent, but also to increase class I MHC (Stark, Kerr et al. 1998) and 
TNF receptor expression on tumor cells (Aggarwal, Eessalu et al. 1985; Tsujimoto, 
Yip et al. 1986), making tumor cells more susceptible to the action of tumor 
necrosis factor alpha (TNFα) and beta (TNFβ), which can trigger apoptosis of tumor 
cells via signaling through the TNF receptor (Szatmary 1999).   
Other than helping to activate tumor-specific CD8+ T cells, the direct role of 
CD4+ T cells in anti-tumor immune responses are often underestimated. CD4+ T 
cells specific for tumor antigens are unable to directly recognize transformed cells 
because many tumors do not express MHC class II molecules. Instead, CD4+ T cells 
recognize, and respond to tumor antigens as presented by professional APCs. 
Despite this limitation, CD4+ T cells are very important components of the anti-
tumor immune response. Tumor-specific effector CD4+ T cells are often required 
for the activation of tumor specific CD8+ cytotoxic T lymphocytes (CTLs) (Janssen, 
Lemmens et al. 2003), but also promote inflammation, which recruits, and 
promotes both innate and adaptive effector cells to exhibit their anti-tumor 
effector functions (Mumberg, Monach et al. 1999).  
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The demonstrated specificity by which CD4+ and CD8+ T cells can be induced in 
response to tumors allows one to infer that each tumor expresses unique antigens 
that can be utilized by the immune system to induce clearance of the tumor 
(Boyse, Old et al. 1962). It was not until the early 1990s that scientists began to 
uncover the antigens expressed by tumors that allow the immune system to 
recognize, and distinguish between normal and neoplastic tissues (Chen, Gure et 
al. 1998; Chomez, De Backer et al. 2001). 
1.2.2.3 Coherence of the humoral and cellular immune responses to linked 
antigens 
It has been appreciated since the early 1970s that the activation of anti-hapten B 
cells, upon interaction with a hapten-carrier conjugate, is aided by the presence of 
carrier-specific T cells (Mitchison 1971). Utilizing these systems it was observed 
that the subclass of antibody generated to the hapten is the same as those 
generated in response to the carrier to which it is linked (Mckinstry, Ismail et al. 
2005). This observed coherence in the isotypes of antibodies generated in 
response to linked antigens is explainable because the cytokines produced by 
antigen-specific T cells greatly influence the decision of a B cell to switch to a 
particular subclass of antibody. It has been demonstrated that CD4+ T helper cells 
of the Th1, Th1/Th2 mixed or Th2 phenotype promote specific B cells to switch to 
IgG2a, IgG1 or IgE antibody isotypes respectively (Coffman and Carty 1986; Bond, 
Shrader et al. 1987; Coffman, Shrader et al. 1987; Murray, McKenzie et al. 1987; 
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Snapper and Paul 1987; Lebman and Coffman 1988; Snapper, Finkelman et al. 
1988). These observations explain the coherence between the phenotypes of the B 
and T cell responses, and suggest that one may be able to indirectly infer the 
Th1/Th2 nature of a immune response by analyzing the relative abundance of 
antigen-specific antibody isotypes (Mckinstry, Ismail et al. 2005). The importance 
and utility of such inferences will become apparent in subsequent sections. 
1.3 The search for tumor antigens 
1.3.1 Tumor antigens recognized by cytotoxic T cells 
It has been appreciated for quite some time that protective immunity to the vast 
majority of syngeneic tumors is mediated by T cells. However, the identity of the 
antigens against which this immunity is generated remained elusive until the early 
1990s. Theirry Boon pioneered the technique of cloning cytotoxic T cells (CTLs) 
from mice/patients suffering from cancer, and determining the antigen specificity 
of these tumor-specific CTLs. This technique involved isolating and cloning CD8+ T 
cells from animals capable of lysing the tumor cell in-vitro. As individual CTL cell 
clones are cultured with the tumor, it places a strong selective pressure upon the 
tumor, and ultimately results in the selection of a set of tumor variants against 
which the selecting CTL cell line is no longer effective. The resulting tumor variants 
selected to be resistant against different CTL clones could be arranged into 
different groups of variants. Members of the same group showed a similar 
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susceptibility or resistance to all the CTL clones, which were also grouped 
according to their ability to lyse each of the respective tumor variants. (Van den 
Eynde, Lethe et al. 1991).  
A cDNA library of the original tumor cell line was generated, and 
transfected into a cell line expressing syngeneic MHC restriction elements, but 
against which none of the established CTL cell lines show endogenous cytotoxicity. 
The resulting transfectants were screened based upon the ability of each of the CTL 
cell lines to lyse these targets. One can thus isolate the gene encoding the 
neoantigen being expressed by the transfectants and which rendered them 
sensitive to particular CTL clone, and identify the proteins to which the immune 
system is mounting a cytotoxic immune response. Using similar techniques, Theirry 
Boon’s group has identified a large number of tumor antigens in both animal and 
human cancers against which a CTL response is generated (Boon, Coulie et al. 
2006).  
1.3.2 The search for tumor antigens recognized by antibodies 
In the 1960s, using techniques that had proven useful in identifying bacterial 
antigens, researchers began immunizing rabbits and other animals with human 
tumors. Investigators attempted to use this hetero-immune serum to identify 
antigens uniquely presented on the surface of tumor cells against which immunity 
is generated (Day 1965). At the time, it was felt the primary insurmountable 
challenge with these protocols was in the difficulty of removing antibodies within 
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the hetero-immune sera reactive with normal cellular proteins present in the 
immunizing tumor. These studies proved to offer very little to the understanding of 
cancer immunity; however, such studies allowed for the identification of many cell 
surface differentiation antigens (Old and Stockert 1977) which have proven 
indispensable to modern immunology. In the 1980s, many researchers attempted 
to overcome the difficulties associated with hetero-immune typing by using a 
patient’s own sera to define antigens presented on the surface of tumor cells 
against which they had developed antibodies (Ueda, Shiku et al. 1979). Like hetero-
immune typing, these attempts at autologous typing of tumor antigens were also 
plagued with many technical problems and were, for the most part, unsuccessful. It 
was not until the discovery and true appreciation of MHC restriction (Zinkernagel 
and Doherty 1974), that it became apparent that the majority of tumor antigens, 
against which immunity is generated, are intracellular proteins not expressed on 
the surface of tumor cells. The technique of Serological Identification of Antigens 
by Recombinant Expression cloning (SEREX) allowed researchers to identify, and 
appreciate the intracellular nature, of the proteins recognized by antibodies in 
autologous sera (Sahin, Tureci et al. 1995). 
The SEREX protocol involves collecting fresh tumor samples from patients, and 
generating a cDNA library from their mRNA. This library is cloned into a λ 
bacteriophage expression vector, and plated onto a lawn of competent E. coli cells. 
The resulting plaques containing the recombinant proteins are blotted onto 
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nitrocellulose. A patient’s serum is pre-adsorbed with E. coli and  bacteriophage 
antigens in an attempt to remove any naturally existing bacterial/viral reactive 
antibodies in the patient’s serum, and the membranes are incubated with this pre-
adsorbed patient’s serum. Positive clones were identified using an alkaline 
phosphatase-conjugated goat anti-human IgG secondary antibody, and were 
visualized using an appropriate detection substrate. Positive clones are isolated by 
exhaustive rounds of immuno-screening. The cDNAs from positive clones were 
sequenced and their identity determined (Sahin, Tureci et al. 1995).  
Although the SEREX protocol is a modern technique, it still poses a lot of 
potential problems. The SEREX technique, as with all techniques using cDNA 
libraries, leads to an over representation of tumor antigens that are expressed at 
high levels. Although increased expression may be important, they may not be 
related to either tumorogenesis or tumor immunogenicity. The SEREX technique 
may underestimate the number of tumor antigens being identified as being 
recognized by the humoral immune system. This likelihood is based in part on the 
use of a prokaryotic expression system. It is very possible that many tumor 
antigens to which the patient has mounted an antibody response are not readily 
produced by transfected prokaryotic cells, as tumor antigens may be normal 
antigens modified and made antigenic by secondary processing events, such as 
glycosylation (Skipper, Hendrickson et al. 1996). It is therefore likely, that the 
protocol does not support the production of all antigenically relevant proteins. In 
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an attempt to at least partially overcome these problems, SEREX protocols should 
be developed using mammalian cell expression systems. Another problem that 
consistently plagues the SEREX protocol is the large number of false positives. A 
source of many of the false positives is the presence of B cells within the tumor 
sample. The cDNA libraries generated from tumor samples that are contaminated 
with B cells will contain many sequences encoding IgG proteins. These 
contaminating immunoglobulin proteins will be detected by the secondary 
antibodies, and result in many false positives (often greater than 90%) (Tureci, 
Sahin et al. 1996). The SEREX protocol has nevertheless proven very effective at 
identifying tumor-associated antigens and, despite being over a decade old, most 
current alternate protocols are simply minor modifications of the original SEREX 
protocol.  
1.3.3 The cancer Immunome 
Scientists, utilizing the above mentioned techniques, have catalogued tumor 
antigens of human cancers that are recognized by the immune system. The 
resulting database, known as the cancer immunome, has allowed scientists to 
compare the relative abundance of different tumor associated antigens among a 
large population of cancer patients. Currently, over 2690 SEREX defined antigens 
have been put into the cancer immunome database 
(http://www2.licr.org/CancerImmunomeDB). There are many potential benefits 
that this information may provide. Firstly, it is very possible that by combining 
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SEREX-defined antigens common to a specific type of cancer, or to cancer cells in 
general, one could effectively generate a protocol by which you could potentially 
diagnose cancer in patients using a simple blood test that assays for the presence 
of a particular type or various combinations of tumor-specific antibodies. These 
SEREX antigens could provide a panel of tumor associated antigens that could be 
used in vaccination trials that attempt to prevent tumors from arising or in trials 
aimed at the treatment of established tumors (Jaffee and Pardoll 1996). 
There have been some comparisons in the literature of the tumor antigens 
recognized by antibodies, CD4+ and/or CD8+ T cells. Results from these studies 
have shown a fairly good correlation between SEREX defined, and antigens 
recognized by CD4 and CD8 T cells (Jager, Jager et al. 2000; Ayyoub, Stevanovic et 
al. 2002). It is not all that surprising that the immune system is mounting a very 
concerted anti-tumor immune response, considering that tumor-specific CD4+ T 
cells are required to activate both tumor-specific B and CD8+ T cells. In this way, it 
may be possible to infer which antigens T cells are responding to by identifying 
SEREX-defined antigens.   
1.3.4 Common tumor antigens 
The realization that some of the tumor antigens against which patients respond 
are common among a wide variety of unrelated cancers was an unexpected, but a 
welcome, observation leading to the suggestion that a vaccine capable of 
protecting people from a wide variety of cancers may be realizable.  The question 
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that arises is how can a wide array of neoplasms, arising in different tissues, as a 
result of different genetic insults, share a common antigenic profile? The answer 
may lie in the rather generic nature of the oncogenic process. Transformed cells 
carry a number of genetic and epigenetic changes. Not all such alterations are 
required to generate, but are merely associated with, a transformed phenotype. 
1.4 De-novo origins of many tumor antigens 
The genetic instability associated with tumor cells results in many genetic and 
epigenetic changes which can effectively alter the panel of proteins produced by 
transformed cells. This altered antigenic profile can be identified and exploited by 
the immune system to enable a discriminatory attack on the neoplasm. In a 
relatively broad stroke, one can effectively define a tumor antigen as any 
difference between tumor and normal cells which allows the immune system to 
distinguish them.  
In most cases, the neoplastic process results from a multi-step process (Fearon 
and Vogelstein 1990), by which a normal cell or group of cells gain a cancerous 
phenotype. With the exception of mutated self- (Disis and Cheever 1996), or viral-
oncogenes (Plata, Langlade-Demoyen et al. 1987), the vast majority of the proteins 
expressed by these altered cells are not unique to the tumor. Instead the immune 
system identifies and kills tumor cells based on their expression of “tumor-
associated antigens”. 
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Many tumor associated antigens are normal cellular proteins having an altered 
pattern of expression in tumor cells as compared to normal cells (Van den Eynde, 
Lethe et al. 1991). It is a common trait for cancer cells to have aberrant expression 
of genes and thus allow immune recognition of transformed cells.  It has become 
increasingly clear that the generation of such neo-antigens does not often require 
any mutation in the genetic information encoded within the primary DNA 
sequence. Transcription from the incorrect DNA strand to produce an anti-sense 
protein or translation ‘out of frame’ (Van Den Eynde, Gaugler et al. 1999), or even 
utilization of cryptic promoters (Guilloux, Lucas et al. 1996) may result in an 
immunogenic variant of a gene from a wild-type DNA sequence. Deficiencies with 
regards to post-transcriptional processing and modifications can also effectively 
introduce de-novo epitopes into a ‘normal’ protein (Skipper, Hendrickson et al. 
1996). Hyperactivation or altered patterns of expression of normal cellular proteins 
has proven itself to be responsible for the generation of many antigenic targets 
against which an anti-tumor immune response is generated. 
Hypomethylation of DNA is a very common occurrence in cancers, and is 
thought to be responsible for many epigenetic changes often seen in transformed 
cells (De Smet, De Backer et al. 1996; Nguyen, Weisenberger et al. 2002). The CpG 
islands are regions in the genome greater than 500 bp in size, having a GC content 
greater than 55%. Quite often the C5 position of the cytosine residues in these CpG 
islands are methylated (Holliday and Pugh 1975; Riggs 1975; Bird 1986). This 
24 
 
methylation affects the chromatin structure, and when it is present in the 
promoter region of any particular gene prevents the recruitment of transactivating 
elements. Aberrant hyper- or hypo-methylation of these CpG islands are often 
found in human cancers (Feinberg and Vogelstein 1983; Gama-Sosa, Slagel et al. 
1983; Bedford and van Helden 1987; Baylin, Belinsky et al. 2000; Baylin and 
Herman 2000; Jones 2002; Florl, Steinhoff et al. 2004). Hypermethylation of CpG 
islands is associated with aberrant gene silencing, while hypomethlyation of 
promoter sequences is associated with aberrant gene activation. This 
hypomethlyation of CpG correlates with the de-novo  expression of normally silent 
genes in transformed cells (De Smet, De Backer et al. 1996), (Sigalotti, Fratta et al. 
2004), and is thought to be responsible for the expression of a unique panel of 
tumor-associated antigens shared among a wide variety of tumors, the most 
common of which have been termed the cancer testis (CT) antigen.   
The CT antigens represent a class of tumor associated proteins whose 
expression is normally restricted to the testis. All CT genes identified to date have 
associated methylated CpG islands in normal somatic tissues, while in cells 
undergoing spermatogenesis, or in neoplastic tissues, these CpG islands are 
unmethylated (Kimmins and Sassone-Corsi 2005). Initially, CT antigens were 
identified based upon detectable immunity against these antigens; however, the 
term CT antigen no longer refers only to gene products to which immune 
responses are generated, but has come to include any gene whose expression 
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profile is normally restricted to the testes and cancer cells. In this light, there are 
44 CT antigen families (Scanlan, Simpson et al. 2004)  CT antigens are further 
categorized as those encoded on the X-chromosome (CT-X antigens), and those 
that are not (CT-non-X antigens). It has been estimated that roughly 10% of the 
genes on the X chromosome belong to the CT-X family (Ross, Grafham et al. 2005; 
Simpson, Caballero et al. 2005). Genes belonging to the CT-non-X family are 
distributed throughout the genome, and do not generally form gene families 
(Grizzi, Chiriva-Internati et al. 2003; Tapparel, Reymond et al. 2003; Xu, Yuan et al. 
2004). These CT antigens are of particular interest to researchers as it is thought 
they constitute promising targets against which vaccines might be developed. 
The question of why many patients uniquely generate immune responses 
to these CT, but not to other tumor associated antigens, is not yet fully 
appreciated.  The process of generating immune responses is a function of both 
the availability of the antigen and the prevalence of precursor T cells specific for 
each particular antigen. More than 40% of mammalian genes are potentially 
regulated by methylation of the cis acting CpG promoter elements, yet the 
upregulation of these genes does not induce detectable immune responses. The 
uniquely immunogenic characteristic of CT antigens is most likely due to their 
normal expression profile. The vast majority of CT antigens are expressed only in 
the testis which is traditionally characterized as an immunoprivileged site (Barker 
and Billingham 1977; Streilein 1995). Normally, cells of the immune system do not 
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survey the testes. Moreover, many nucleated cells in the testes express very little, 
if any, class I MHC molecules on their surface (Hotta, Nagata et al. 2000). In this 
light, it is likely the immune system is unable to maintain effective tolerance to 
these CT proteins, and precursor T cells specific to these proteins are able to 
accumulate in the periphery of normal animals (Valmori, Souleimanian et al. 2005). 
When tumor cells develop, CT proteins become expressed outside traditional, 
immunoprivileged sites, and the cells of the immune system in the periphery are 
capable of both recognizing, and mounting an immune response to these 
aberrantly expressed proteins.  
Although the expression of tumor-associated antigens may vary 
considerably between different cancer patients, in the same type of cancer, and 
even among the cellular population of a single tumor, Thierry Boon and others 
have shown the presence of tumor antigens that are shared by a number of 
different tumors and patients (Boon, Cerottini et al. 1994; Van den Eynde and van 
der Bruggen 1997). These observations lead to the suggestion that most tumor-
associated antigens result from generic changes that are common among different 
cancers. These observations support the hope that a universal anti-cancer vaccine 
can be developed. 
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1.5 Potential functions of tumor-associated antigens 
Expression of tumor associated antigens may merely be associated with 
transformed cells, and simply act as a target for immune attack, or be required for 
the oncogenic state. If one proposes to use particular CT antigens as potential 
targets for vaccine development, it would be advantageous if the proposed targets 
were required to maintain the neoplastic phenotype. This may decrease the 
plasticity of their expression profile in the tumor, and increase the effectiveness of 
the vaccine. 
Recent data suggest that CT antigens, such as melanoma associated gene 
expression (MAGE) proteins, may play an active role in tumor development. MAGE 
is a family of CT antigens consisting of more than 25 genes characterized by the 
presence of a large central region termed the MAGE homology domain (MHD) 
(Chomez, De Backer et al. 2001). This MHD does not contain any regions of 
significant homology with other known proteins (Taniura, Kobayashi et al. 2005).  
Currently, the only CT-X gene product whose protein binding partner has been 
found is MAGEA1. MAGEA1 has been shown to interact with the transcriptional 
regulator SK1-interacting protein (SKIP) (Laduron, Deplus et al. 2004). SKIP 
connects DNA-binding proteins to other proteins that either activate or repress 
transcription, and participates in many signaling pathways. It has been proposed 
that MAGE1A, through its interaction with SKIP, may actively repress the 
expression of genes required for differentiation by disrupting SKIP-mediated 
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NOTCH-1 signal transduction by binding SKIP and recruiting histone deacetylase 
(Laduron, Deplus et al. 2004), which may act to disregulate cell proliferation and 
promote the survival of transformed cells (Wharton, Johansen et al. 1985; Laduron, 
Deplus et al. 2004). 
 It has been proposed that other CT antigens may render tumor cells more 
resistant to immune-mediated killing. For example, members of the GAGE family, 
such as GAGE7C or GAGE7B, may increase resistance to apoptosis induced by 
either INF or by the death receptor FAAS (Cilensek, Yehiely et al. 2002). It has also 
been found that expression of at least one of MAGEA1, MAGEA2, or MAGEA3 
proteins appear to render cells more resistant to TNF-mediated cytotoxicity (Park, 
Kong et al. 2002). Such observations have led LJ Old to propose his theory that a 
‘Gametogenic Program’ is induced in cancer cells. According to this theory, these 
germline genes confer a range of phenotypic traits that are essential for the 
survival and function of gametes, and such traits would prove advantageous for 
tumor cells (Old 2001). 
1.6 Failure of the immune system to control cancer  
As discussed in the above sections, protective anti-tumor immunity is relatively 
simple to establish in many/most experimental systems, and studies in both 
experimental animals and humans have shown that both cellular and humoral 
immune responses are generated in the presence of a progressively growing 
tumor. The question that arises is why this immunity fails to offer protection 
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against the tumor. Many theories are presented in the literature that attempt to 
explain the mechanisms by which the immune system fails cancer patients.  
1.6.1 Immune ignorance  
The tumor associated antigens recognized by the immune system could be 
considered as being slightly altered self antigens. Proponents of Janeway’s 
(Janeway 1989) ‘infectious-nonself’ and Matzinger’s (Matzinger 1994) ‘danger’ 
models of CD4+ T cell activation suggests a developing tumor fails to produce 
appropriate inflammatory or ‘danger’ signals that are envisaged to be essential in 
the activation of the naïve T cells specific for tumor antigens. These theories of 
immune ignorance have inspired many studies using various dendritic cells, and 
viral vectors expressing tumor antigens, in an attempt to overcome the 
unresponsiveness to tumor antigens envisaged to result in the failure to generate 
protective immunity (Schuler, Schuler-Thurner et al. 2003). A vast majority of these 
therapies has not had any appreciable efficacy as assessed in clinical trials. 
Furthermore, studies in tumor bearing animals which were treated with tumor 
cells transfected to express the immunocostimulatory B7 molecule on the cell 
surface had a favorable affect in inducing tumor regression only if given while the 
primary tumor was very small (Chen, Linsley et al. 1993). Such results, coupled with 
the striking observation that even in patients with progressively growing tumors, T 
cells capable of killing tumor cells in-vitro can often be easily identified from both 
the blood (Letsch, Keilholz et al. 2000) and tumor infiltrates (Lurquin, Lethe et al. 
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2005), have led others to suggest that the failure of the immune system is most 
likely not at the level of initiating the priming of T cells.  
1.6.2 Tumor variants 
Antigenic variability in tumors was first shown experimentally in 1977, when it was 
observed that tumor cells isolated from an animal after partial rejection of the 
tumor were much less sensitive to lysis by the CD8+ T cells isolated from these 
animals than were the original tumor cells (Biddison and Palmer 1977). In the early 
1980s, Boon et al. demonstrated at late time points during tumor progression that 
animals were able to clear in-vitro passaged clones from which the progressively 
growing tumor was derived, but not cells from the established, progressively 
growing, tumor (Uyttenhove, Maryanski et al. 1983). These observations have 
given rise to the idea that the immune system itself places a very heavy selection 
pressure on the tumor, whose antigenic profile is inherently very plastic, 
continually selecting tumors expressing an altered antigenic profile not recognized 
by the pool of tumor-specific effector cells. This theory proposes the immune 
system is simply unable to keep pace with the continual generation of these tumor 
variants ultimately resulting in immune failure.  Opponents of this theory often 
point to the simple fact that for the vast majority of murine syngeneic tumors, 
researchers have devised relatively simple strategies to render mice resistant to a 
normally lethal dose of the selecting tumor (Foley EJ, 1953; Klein G, 1959; Klein G, 
1960). These findings suggest that the immune system, if significant numbers of 
31 
 
variants do arise, is capable of killing all these variants. Furthermore, the immune 
system usually responds to several epitopes derived from several different 
polypeptides on a tumor, and for a tumor variant to escape killing by the immune 
system, and predominate, it would have to simultaneously mutate, or lose the 
expression of, several proteins at one time. In fact, it has been reported by Boon 
and colleagues that in more than ninety percent of cases, metastatic tumor cells 
isolated from patients during the course of disease are capable of restimulating 
and being lysed by autologous T cells isolated from patients early in the course of 
tumor progression (Boon, Coulie et al. 2006). Such considerations suggest there 
may be other reasons for the failure of the immune system to effectively contain 
tumors. 
1.6.2.1 Concomitant Immunity 
Concomitant immunity is defined as being present at a period of time, after 
implantation with a lethal dose of isogenic tumor cells, during which the animal is 
capable of preventing the outgrowth of another normally lethal dose of the same 
tumor at a second injection site.  The presence of such immunity generally peaks 
early during the course of tumor growth, and quickly decays over time (North and 
Bursuker 1984).  Lymphocytes harvested from tumor-draining lymph nodes two or 
three days after implantation of a syngeneic sarcoma were able to inhibit the 
growth of the selecting tumor cells in-vitro (Rosenau and Moon 1966). Spleen cells 
harvested from an animal bearing a progressively growing tumor during this period 
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of concomitant immunity were able to, upon transfer, protect a naïve mouse from 
a normally lethal challenge with the selecting tumor (Greene 1980). Such 
observations strongly suggest that even in the presence of a progressively growing 
tumor there is an immune response capable of efficiently killing tumor cells (Takei, 
Levy et al. 1976).  
1.6.3 Suppressor cells 
For over forty years, it has been appreciated that there is a population of T cells 
within animals carrying a late stage progressively growing tumor which are capable 
of specifically suppressing the stable generation of an effective anti-tumor immune 
response upon transfer into naïve animals (Eggers and Wunderlich 1975; Fujimoto, 
Greene et al. 1976; Small and Trainin 1976; Reinisch, Andrew et al. 1977). The 
existence of such a suppressor population has been demonstrated both in-vitro 
and in-vivo using different tumor models (Gershon and Kondo 1971; Takei, Levy et 
al. 1977; North 1984; North and Bursuker 1984). Cells isolated from the draining 
lymph nodes two or three days after implantation of a syngeneic sarcoma were 
able to inhibit the growth of the selecting tumor cells in-vitro (Rosenau and Moon 
1966). Spleen cells from mice with an established P815 tumor had T cells capable 
of specifically suppressing the in-vitro generation of specific cytotoxicity against 
P815 (Takei, Levy et al. 1976; Takei, Levy et al. 1977). The suppressor function of 
these cells are not restricted to either the K or D MHC loci, so they are probably 
CD4+ T cells (Levy, Maier et al. 1979).   
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Many investigators have examined the development of these suppressor 
cells in relation to the observations of concomitant immunity. Greene was able to 
demonstrate that progression of the primary tumor was associated with the 
disappearance of detectable concomitant immunity (Greene 1980). RJ North and 
colleagues subsequently demonstrated that the observed loss of concomitant 
immunity was due to a progressive increase in the numbers of the so called 
‘suppressor cells’ which he demonstrated bear the Ly1+,2- marker (CD4+ T cells) 
(Bursuker and North 1984; North and Bursuker 1984). These observations mirror 
those by D.G. Kilburn and colleagues who demonstrated that spleen cells of mice 
with an established P815 tumor had T cells capable of specifically suppressing the 
in-vitro generation of specific cytotoxicity against P815 (Takei, Levy et al. 1976; 
Takei, Levy et al. 1977). If these CD4+ suppressor T cells are responsible for 
immune failure, then an understanding of their generation and mode of action is 
central to the development of effective anti-tumor immunotherapeutic strategies.   
1.6.4 Suppressor cells in a modern world 
The idea of suppressor T cells as a mechanism of immune failure with regards to 
cancer fell out of vogue in the mid-eighties and had remained essentially an 
afterthought in the literature until the late 1990s. At that time, essentially two 
revolutionary ideas helped to put suppressor cells back onto the immunological 
map. Firstly, as discussed above, T. Boon and L.J. Old’s pioneering work in the 
development of the cancer immunome (Lee, Obata et al. 2003; Boon, Coulie et al. 
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2006) had unexpectedly added a new depth of analysis by demonstrating that the 
vast majority of tumor antigens are normal cellular proteins.  The second dramatic 
finding was the existence of what are now known as CD4+ CD25+ Foxp3+ T 
regulatory cells (Sakaguchi, Sakaguchi et al. 2001; Sakaguchi 2005). Many groups 
have reincarnated suppressor cells in the guise of CD4+ CD25+ Foxp3+ T regulatory 
cells.  
1.6.4.1  Suppressor T cells as CD4+ CD25+ Foxp3+ regulatory T cells 
Over thirty years ago, it was observed, in certain strains of mice, that thymectomy 
three days after birth resulted in the subsequent development of organ-specific 
autoimmunity (Nishizuka and Sakakura 1969). This autoimmunity induced by day 
three thymectomy could be prevented by transferring CD4+ T cells from the 
spleens of adult or thymocytes from day ten mice to recipients shortly after 
thymectomy (Penhale, Irvine et al. 1976; Sakaguchi, Takahashi et al. 1982; 
Sakaguchi, Fukuma et al. 1985). Such observations strongly suggest the existence 
of a population of T cells capable of controlling the development of autoimmunity. 
Further studies have characterized these cells as having constitutive high level 
expression of the alpha chain of the IL-2 receptor (CD25) (Sakaguchi, Sakaguchi et 
al. 1995) and the transcription factor foxp3 (Hori, Nomura et al. 2003). These cells 
have been called regulatory T cells, and have been shown to actively inhibit the 
function of a wide variety of immune cells usually in a cell-contact dependent 
manner (Murakami, Sakamoto et al. 2002; Azuma, Takahashi et al. 2003; 
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Trzonkowski, Szmit et al. 2004; Lim, Hillsamer et al. 2005; Romagnani, Della Chiesa 
et al. 2005; Chen 2006). The recent literature has become inundated with reports 
of CD4+ T regulatory cells which regulate the generation or function of other T 
cells. Initially, it was thought that these natural CD4+CD25+ regulatory T cells which 
are found in the thymus, might be selected to have a specificity repertoire focused 
on self antigens, and hence have a major role in the maintenance of peripheral 
tolerance through a modified mechanism of ‘infectious tolerance’ (Piccirillo and 
Shevach 2004). More recently, it has been observed that these regulatory T cells 
also play a role in many models of infectious disease, and that they have specificity 
for foreign pathogens (Belkaid and Rouse 2005).   
 The evolution of the cancer immunome has quickly forced scientists to 
realize that the vast majority of tumor-associated antigens, to which patients are 
mounting immune responses, are in fact non-mutated, normal cellular proteins. As 
such, many theories of immune failure against tumors involve the proposal that 
such ‘self’ tumor-associated antigens induce a particular class of T cell, namely 
CD4+CD25+ natural T regulatory cells, which dampens the ability of the immune 
system to generate an effective anti-tumor immune response (Murakami, 
Sakamoto et al. 2002; Shevach 2002; Azuma, Takahashi et al. 2003; Dunn, Old et al. 
2004; Trzonkowski, Szmit et al. 2004; Lim, Hillsamer et al. 2005; Romagnani, Della 
Chiesa et al. 2005; Sakaguchi 2005; Chen 2006). In fact, treatments to reduce the 
number of CD25+ T cells in-vivo have shown positive effects in some tumor models 
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(Onizuka, Tawara et al. 1999; Shimizu, Yamazaki et al. 1999; Steitz, Bruck et al. 
2001; Sutmuller, van Duivenvoorde et al. 2001; Golgher, Jones et al. 2002; Casares, 
Arribillaga et al. 2003; Ko, Yamazaki et al. 2005; Prasad, Farrand et al. 2005).   
The observations described above suggest a potentially powerful role for 
CD4+CD25+ T regulatory cells in the inhibition of protective anti-tumor immune 
responses.  However, one must be aware that the reinterpretation of suppressor 
cells as T regulatory cells contravenes many classical observations made in both 
tumor and non-tumor systems.  
1.6.4.2 An argument against T regulatory cells as mediators of immune 
failure 
On the whole, there are relatively few in-vivo murine studies which demonstrate 
that depletion of CD25+ T cells induces tumor regression (Zou 2006). In most 
models, one must deplete CD25+ T cells before, or very soon after, tumor 
implantation to have any measurable effect on tumor growth (Onizuka, Tawara et 
al. 1999). Such observations are surprising when put into the context of 
concomitant immunity. If CD25+ T cells are the prime cause that an effective anti-
tumor immune response fails to be generated, one would predict that depletion of 
CD25+ cells at any point before concomitant immunity begins to wane should 
result in the generation of protective immunity. Furthermore, the implication of a 
preexisting regulatory T cell population specific for tumor antigens in naïve animals 
is not easily reconciled with the simple observation that, in most experimental 
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models of cancer, it is very simple to generate protective anti-tumor immune 
responses (Arca, Krauss et al. 1996; Ashley, Faiola et al. 1997; DeMatos, Abdel-
Wahab et al. 1998; Schreurs, de Boer et al. 1998; Tuting, Steitz et al. 1999). One 
must reconcile such observations by postulating that there are selective and 
differential requirements for the activation of T regulatory cells as compared to 
effector T cells; however, no one has proposed such a model that accounts for the 
generation and decay of concomitant immunity.  
Robert North and colleagues observed that in some tumor models, one could 
preferentially inhibit the generation of suppressor cells by treatment with 
cyclophospamide (Awwad and North 1989) or with low levels of irradiation (North 
1986). These observations led to the thought that suppressor cells were more 
sensitive to anti-proliferative treatments than protective cells. It has subsequently 
been extrapolated that CD4+CD25+ regulatory T cells must also be exceptionally 
sensitive to anti-proliferative treatments (Thornton, Piccirillo et al. 2004; Ercolini, 
Ladle et al. 2005; Motoyoshi, Kaminoda et al. 2006). There have been calls to utilize 
low doses of cyclophosphamide to inhibit the effects of T regulatory cells in all 
immunotherapeutic tumor treatment strategies (Ghiringhelli, Larmonier et al. 
2004; Turk, Guevara-Patino et al. 2004). It is somewhat surprising that a 
hyporesponsive regulatory cell be more sensitive to such treatments compared to 
the rapidly dividing T cells that differentiate into effector T cells. Furthermore, 
Takei et al., demonstrated in-vitro that their suppressor cells, when diluted, 
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effectively become T helpers (Takei, Levy et al. 1977). One could interpret such 
observations as having their effect by simple virtue of limiting T cell cooperation. 
As described in previous sections, there is evidence suggesting that the degree 
to which specific CD4+ T cells are able to cooperate can determine the Th1/Th2 
nature of an immune response. This degree of cooperation can be modulated by 
altering the number of specific, and interacting CD4+ T cells or by altering the dose 
of antigen. In support of such a model, experimental evidence has demonstrated 
that decreasing either the number of CD4+ T (Ismail and Bretscher 2001; Ismail, 
Basten et al. 2005; Mckinstry 2005), or the antigen load (Bretscher, Wei et al. 1992; 
Menon and Bretscher 1998; Power, Wei et al. 1998; Hailu, Menon et al. 2001; 
Ismail and Bretscher 2001; Ismail, Basten et al. 2005), can modulate a predominant 
Th2 or mixed Th1/Th2 response towards the Th1 pole. In the subsequent sections 
we will discuss how several successful attempts at modulating tumor-specific 
responses can be interpreted as a consequence of limiting the degree of CD4+ T 
cell cooperation, which we hypothesize to promote the generation of Th1 
responses, which are more effective than Th1/Th2 mixed responses at containing 
the outgrowth of neoplastic cells.      
1.6.4.3 Possible effects of CD25 monoclonal antibody treatment on T cell 
cooperation 
The vast majority of studies examining the effects of in-vivo depletion of CD25+ 
cells utilize the PC61 B cell hybridoma  (Shimizu, Yamazaki et al. 1999; Imai, Saio et 
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al. 2007) which has been shown to produce a monoclonal antibody recognizing the 
alpha-chain of the IL-2 receptor. Binding of this antibody to CD25 on the surface of 
T cells prevents subsequent IL-2 binding (Lowenthal, Corthesy et al. 1985). IL-2 is 
the most important T cell growth factor and it is therefore possible, by blocking the 
function of IL-2, that this anti-CD25 treatment may have many powerful 
phenotypic consequences other than simply depleting a small population of 
CD4+CD25+ T cells. Perhaps the effects one observes could also be due to limiting 
the degree of T cell cooperation in the generation of the anti-tumor immune 
response. 
Ultimately, one must concede that the role of CD4+CD25+ regulatory T cells in 
a normal physiological state and their role in promotion of disease remain to be 
fully understood. Until one understands this population of cells better, it is perhaps 
wise to remain cautious in promoting the general assumption that T regulatory 
cells are in fact the sole purveyors of the phenotypic ‘tolerance’ in cancer patients 
to their progressively growing tumor. It is very likely these cells may simply be one 
cog in the wheel of immune failures associated with progressive tumor growth.  
1.6.5 Classical suppressor T cells 
It has been appreciated for many years that humoral and cell mediated immunity 
tend to be mutually exclusive of one another (Parish 1972). Early observations 
supported the idea that the generation of each class of immunity was also 
associated with the generation of antigen-specific T cells that acted to suppress the 
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generation of the opposing class of immunity. Experimentally it has been shown 
that generation of a humoral immune response against a particular antigen results 
in the generation of a population of CD4+ (Ly1+Ly2-) T cells which, upon transfer, 
renders naïve, recipient animals refractory for the induction of cell mediated 
immunity, in the form of delayed type hypersensitivity, to the same antigen 
(Lagrange, Mackaness et al. 1974; Ramshaw, Bretscher et al. 1976; Ramshaw, 
McKenzie et al. 1977). The specificity of suppression is a primary facet of both the 
suppressor cells reported by North and colleagues (Bursuker and North 1984; 
North and Bursuker 1984), as well as the classical suppressor CD4+ T cells discussed 
above; however, this specificity of action is not known to be shared by regulatory T 
cells. It is commonly thought that although regulatory T cells are generated in 
response to specific antigens, their mode of action is not antigen-specific (Shevach 
2002). Such observations, to my mind, do not support the idea that the suppressor 
T cells described by North in his tumor systems are CD4+ CD25+ natural T 
regulatory cells. We support the idea that these suppressor cells act to specifically 
maintain the exclusivity of humoral (Th2) and cell mediated (Th1) immune 
responses to specific antigens.  
1.6.6     Suppressor T cells and the Th1/Th2 paradigm 
It has been appreciated in some situations that clinical infectious diseases are not 
due to a lack of specific immunity, but rather due to the generation of immunity 
ineffective at containing the pathogen (Bretscher, Ismail et al. 2001). It has been 
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suggested for quite some time, that such a paradigm also exists in tumor 
immunology. For fifty years it has been suggested that the generation of cell 
mediated immunity to tumor antigens correlates with protection, while disease 
progression is associated with humoral immunity to tumor antigens. In 1968, 
George Klein stated that “It will be most important to establish what variables 
of…immunization…dosage, route of administration, and timing [of antigen 
administration] are critical to achieve the objective, which seems to be a 
stimulation of host cell-mediated rejection with minimum risk of antibody-
mediated enhancement” (Klein 1968). In a modern sense, one may propose 
induced resistance as being a form of Th1- immune deviation. In such a model, Th1 
type responses are effective in containing tumors, while Th2 type responses 
against tumor antigens are ineffective in containing the outgrowth of tumor cells 
and normally occur during tumor progression.  
It has been clearly demonstrated by North that the kinetic development and 
subsequent extinguishment of concomitant immunity is associated with the 
development of tumor-specific suppressor CD4+ T cells (North 1984; North and 
Bursuker 1984). It is possible to envisage that concomitant immunity and its 
extinction correlate with cell-mediated Th1 immunity and with the evolution of a 
substantial Th2 component of the immune response. This hypothesis is attractive 
in part because it explains the parallel nature of the evolution of the Th1/Th2 
nature of the immune response with North’s findings in tumor systems. The 
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observations of Salvin (Salvin 1958), are parallel to, and predate by several 
decades, observations made with replicating antigens. Mice given a sufficiently low 
number of a slowly replicating microorgansism only generate INFγ producing Th1 
cells. Mice given a high number of replicating microorganisms produce an initial 
wave of specific CD4+ T cells secreting INFγ, corresponding to Th-1 cells, which is 
subsequently replaced by either a mixed Th1/Th2, or a predominant Th2 immune 
response, as assessed by specific IL-4 production by CD4+ T cells. (Bretscher, Wei et 
al. 1992; Power, Wei et al. 1998; Bretscher, Ismail et al. 2001). The idea of 
suppressor cells being tumor-specific Th2-type cells may offer an additional 
explanation for many observations in many models of immunological treatment of 
cancer, as I shall comment upon in the discussion.  
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2 Research Objectives 
The mechanisms by which the immune system fails to protect against cancer are 
not well understood. The primary goal of this research is to attempt to understand 
the types of immunity generated in mice suffering from progressive tumor growth 
as compared to mice rendered resistant to a normally lethal challenge of the same 
tumor. Such understanding, in the future, will enable one to develop strategies to 
exploit the endogenous immunity generated against cancer to develop better 
treatments. 
Utilizing experimental animal models by which one can render mice resistant 
to a normally lethal challenge with either the P815 or L5178Y tumors, I sought to 
develop assays to test the hypothesis that the Th1/Th2 nature of the anti-tumor 
immune response is correlated with tumor resistance/susceptibility. I also sought 
to exploit any correlates found to design and test strategies to induce tumor 
regression. 
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3 Materials and Methods 
3.1 Mice 
DBA/2J mice were either obtained from Jackson Laboratories (Bar Harbor, Maine, 
USA) or from the University of Saskatchewan animal colony. CBA/J mice were 
obtained from the University of Saskatchewan animal colony. Mice were housed 
under specific-pathogen free conditions, and were routinely screened to ensure 
they were free of subclinical viral and bacterial infections. Male and female mice 
used in experiments were between the ages of 6-12 weeks. All animals were 
maintained according to the guidelines of the Canadian Council of Animal Care. 
3.2 Cell lines 
3.2.1 Tumor cell lines 
P815 was derived from a male DBA/2 mouse by painting its skin with 0.2% 
methylcholanthrene in ether three times a week for seven weeks (Dunn and Potter 
1957), and was obtained as TIB-64, Lot#2310374, from the American Type Culture 
Collection, Rockville, Maryland, USA. L5178Y is a thymoma induced by 
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methylcholanthrene in ether, kindly provided by Dr. RJ. North, Trudeau Institute, 
Saranac Lake, NY, USA. 
3.2.2 B cell hybridomas 
11B11 (HB-188) is a rat hybridoma secreting monoclonal IgG1 antibodies capable 
of neutralizing murine IL-4 (America Type Culture Collection) (Ohara and Paul 
1985). GK1.5 is a rat hybridoma secreting monoclonal IgG2b antibodies capable of 
binding to the mouse CD4 antigen. This hybridoma was obtained from the 
American Type Tissue Culture Collection (Dialynas, Quan et al. 1983). 
3.3 Media 
RPMI 1640 media supplemented with L-glutamine and Leibovitzovitz media were 
prepared from powdered stocks per the manufacturer’s instructions (Gibco 
Laboratories, Grand Island, NY, USA). Media was sterilized by passage through a 
0.22 m filter (Millipore, Molsheim, France). RPMI 1640 media was further 
supplemented with 10% fetal bovine sera (Hyclone, Logan, UT, USA), 100 U/ml 
penicillin/streptomycin (Gibco), 0.8 mM sodium pyruvate, and  5x10-5 M -
mercaptoethanol to make RPMI complete media that was used for all in-vitro 
cultures. When required, Leishmania major parasites were grown in RPMI 1640 
media at a 1:1 ratio with 199 media (Gibco) supplemented with 20% fetal bovine 
sera (Hyclone).  
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Calcium and magnesium-free phosphate-buffered saline (PBS) was prepared as 
a 10x stock solution (pH ~7.0) containing 80.0 g/L NaCl, 2.0 g/L KCl, 11.5g/L 
Na2HPO412H2O, and 2.0g/L KH2PO4 in 1L distilled deionized H2O. PBS was used as a 
1x solution, and was autoclaved as required. 1x PBS was supplemented with 
0.075% Tween 20 to make PBST. 
3.3.1 Parasites 
Leishmania major strain, MHOM (WHO MHOM/IL/80/Friedlin) were used to infect 
mice subcutaneously into the hind foot pad with stationary phase promastigotes in 
a volume of 20L RPMI 1640:199 serum-free media.   
3.4 Preparation of single cell suspensions 
3.4.1 Spleen cells 
Mice were killed by cervical dislocation. The spleen was aseptically removed, and 
was placed into 10 ml of ice cold Leibovitz media. The spleen was cut up into small 
fragments, and a single cell suspension was obtained by gently pressing these small 
fragments through a 60 gauge stainless steel wire mesh. The resulting suspension 
was transferred to a 15 ml tube, and was left for approximately 2 minutes to allow 
debris to settle. Nine ml of the supernatant was collected, and spun by 
centrifugation at 500 x g for 10 minutes at 4° C.  Cell viability was determined using 
trypan blue exclusion using a hemocytometer slide. 
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3.4.2 Peripheral blood leukocytes  
Mice were warmed under a heating lamp for approximately 10 minutes, and 10-12 
drops of blood (roughly 250 l) was collected from their tail into a sterile tube 
containing roughly 20 units of heparin. When necessary, the blood was spun at  
500 x g for 10 minutes and the sera was collected and stored at -20º C until use. 
Blood was mixed with 1 ml of cold Leibovitz media, and red blood cells were 
removed by density gradient centrifugation for 20 minutes at 890 X g on 1 ml of  
Ficoll  400 (Pharmacia Biotech AB, Uppsala, Sweden). Cells at the interface were 
harvested, placed into 10 ml of cold Leibovitz medium, washed once, and 
resuspended into a final volume of 1.5 ml RPMI complete medium. Cell viability 
was determined using trypan blue exclusion, and cells were counted using a 
hemocytometer slide. 
3.5 Nylon wool purification of spleen cells 
Nylon wool fiber (Polysciences Inc. Warrington, PA, USA) was washed and 
autoclaved in saline a minimum of three times prior to use. Columns were 
prepared by placing roughly 6ml of lightly packed nylon wool into a 10 ml syringe 
with a 23 gauge needle attached. The column was washed by running 20 ml of 
Leibovitz medium through the column. The column was blocked by running 10 ml 
of warm Leibovitz media supplemented with 10% fetal bovine serum through the 
column, and placing it in a 37 C incubator for a minimum of 2 hours before use. 
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One spleen in a volume of three ml warm Leibovitz medium supplemented with 
10% FBS was layered on the top of the column, and allowed to run until the entire 
suspension entered the nylon wool. The column was incubated at  37 C for one 
hour, and non-adherent cells were eluted by running 40 ml of warm Leibovitz 
medium supplemented with 10% FBS through the column. This eluted fraction was 
collected, and the fractionated cells were counted. Percent recoveries ranged 
between 20-35%.  
3.6 Magnetic activated cell sorting (MACS) fractionation of spleen cells 
Red blood cells were removed from spleen cells by resuspending spleen cells in 3 ml of 
Leibovitz medium per spleen. 5 ml of filter-sterilized ACK lysing buffer (0.15M NH4Cl, 1mM 
KHCO3, 0.1mM Na2EDTA, pH 7.2) was added, and left at room temperature for 3 minutes. 
Cells were filtered through a 30 m nylon mesh filter to remove cellular debris, and the 
remaining cells were washed 3 times in Leibovitz medium. Cells were resuspended in 
MACS buffer (5% fetal calf serum in PBS) at a concentration of 1.1x108 cells/ml. 10 L of 
appropriate magnetically labeled antibodies (anti-CD4, CD8 and Thy1.2) (Milteni Biotec, 
Bergisch Gladbach, Germany) were added per 107 cells (90L of cell suspension). After 
mixing, the mixture was left to incubate for 15 minutes at 4C. Cells were washed in, and 
then resuspended in 500L of MACS buffer. Depletion (LD) columns were placed in the 
magnet, washed with 3 ml of MACS buffer, and the cell suspension was applied to the 
column. The unlabeled fraction was collected by washing the column three times with 3 ml 
MACS buffer. Positively labeled cells were collected by removing the column from the 
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magnetic field, and flushing the column with 5 ml MACS buffer. Purity of each fraction was 
confirmed by flow cytometry. 
3.7 Flow cytometry 
Spleen cells or cells harvested after in-vitro culture were washed twice, filtered through a 
30 m nylon mesh filter to remove any clumps, and cells were resuspended at a final 
concentration of 107 cells per ml PBS supplemented with 5% FCS (FACS buffer). 100 l of 
the suspension was labeled with 7-10 L of FITC or PE-labeled antibodies (anti-CD4 (YTS 
191.1.2 clonotype), anti-CD8a (YTS 169 AG 101 HL clonotype), anti-CD19 (6D5 clonotype), 
anti-CD45R (RA3-6B2 clonotype), anti-CD90 (Thy 1.2; 5a8 clonotype), anti-/ TCR (H57-
597 clonotype), anti-I-Ad (34-5-3S clonotype) (Cedarlane Laboratories Limited, Hornby, 
Ontario, Canada) anti-H-2Dd (34-2-12 clonotype) (BD Biosciences, Franklin Lakes, NJ, USA). 
Cells were incubated on ice for 30 minutes, washed, and resuspended in one ml FACS 
buffer. Labeled cells were examined using a Beckman Coulter Epics Flow cytometer, and 
were analyzed using the Expo 32 v1.2 software package (Coulter, Mississauga, ON, 
Canada).   
3.8 ELISPOT assay 
3.8.1 Preparation of ELISPOT plates 
96-well Unifilter 350 nitrocellulose bottom plates (Whatman-Polyfiltronics, Clifton, 
NJ, USA) were coated with either 0.1 g purified anti-IL-4 (11B11) or anti-INF (R4-
6A2) monoclonal antibodies (Pharmingen, San Diego, CA, USA) per well in 1M 
bicarbonate buffer at a pH of 9.6. Plates were left at 4C overnight. Plates were 
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washed once with RPMI, and subsequently blocked for at least 2 hours with 
complete-RPMI before use. 
3.8.2 ELISPOT assay for the detection of P815-Dependent INF and IL-4 secretion 
by spleen cells 
Spleen cells harvested from mice exposed to the P815 tumor were prepared, and 
purified on nylon wool columns. This enriches for T cells, and eliminates the 
majority of contaminating tumor cells. These primed spleen cells are plated at 
various dilutions with the addition of spleen cells from normal mice to obtain a 
total of 2x106 spleen cells/well. This complementation with normal spleen ensures 
the number of APC is not limiting the detection of antigen-specific T cells, making 
the assay highly sensitive and valid for enumerating effector T cells. 5x105 gamma-
irradiated P815 cells (~20 000 Rads) were used as antigen. Plates were allowed to 
incubate at 37 C in a 5% CO2 atmosphere for 8 hours. 
3.8.3 ELISPOT assay for the detection of L5178Y-dependent cytokine secretion 
by spleen cells 
Spleen cells harvested from mice exposed to the L5178Y tumor were prepared, and 
plated at various dilutions with the addition of spleen cells from normal, non-
immunized mice to obtain a total of 1x106 spleen cells per well. 1x105 gamma-
irradiated L5178Y cells (~20 000 Rads) were used as antigen. Plates were allowed 
to incubate at 37 C in a 5% CO2 atmosphere for 8 hours. 
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3.8.4 ELISPOT assay for the detection of Leishmania major-dependent 
cytokine secretion by spleen cells 
Spleen cells harvested from L. major infected mice were prepared and plated at 
various dilutions with the addition of spleen cells from normal, nom-immunized 
mice to obtain a total of 1x106 spleen cells per well. 30 g/ml of freeze-thawed 
sonicated L. major was added as antigen to appropriate wells (Power, Grand et al. 
1999; Uzonna and Bretscher 2001). Total protein content of antigen was 
determined by the bicinchoninic assay protein reagent (Pierce, Rockford, IL). Plates 
were allowed to incubate at 37 C in a 5% CO2 atmosphere for 8 hours. 
3.8.5 Development of Spots in the ELISPOT assay 
Cells were removed from the plate by washing twice with PBST. Any remaining 
cells were lysed by washing the plate with ddH2O. Residual cellular debris was 
removed by washing the plates an additional four times with PBST. 1.0 g/ml PBST 
of biotinylated anti-INF (XMG1.2) or anti-IL-4 (BVD6-24G2) (BD PharMingen, 
Mississauga, ON, Canada) was added to appropriate wells. The plates were 
incubated at 4C overnight. Plates were then washed eight times with PBST to 
remove any unbound antibodies, and 100 L of alkaline-phosphatase strepavidin 
(Jackson Immuno Research Laboratories Inc., West Grove, PA, USA) at a 
concentration of 0.2 g/ml in PBST was added to each well, and allowed to 
incubate at room temperature for 1.5 hours. Plates were then washed eight times 
with distilled water, and 100 L of NBT/BCIP (Roche, Basel, Switzerland) diluted 
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1:50 in substrate buffer (0.1 M Tris-HCl, pH 9.5, 0.1 M NaCl, and 0.05 M MgCl2). 
Spots were allowed to develop in the dark, and the color reaction was stopped by 
washing the plates three times with distilled water. Plates were allowed to dry, and 
spots were enumerated using a dissecting microscope. 
3.9 Western blot to detect P815-specific antibodies 
3.9.1 P815 antigen 
P815 cells were harvested from in-vitro culture, washed 4 times in sterile PBS and 
resuspended at 108cells/ml. The cell suspension was freeze/thawed, and sonicated 
for 24 cycles on ice using a Branson Sonifer 450 (Branson, Danbury, CT, USA) set at 
50% duty cycle. When required, the soluble and insoluble fractions were separated 
by spinning the resulting suspension for 30 minutes at at 20 000 x g. The soluble 
fraction was collected, and the insoluble fraction was re-suspended in an 
equivalent volume of fresh PBS (sonicated 3-4 times to resuspend the pellet). The 
P815 antigen was stored at -20C until use.  
3.9.2 Western blot 
P815 antigen samples were diluted 1:1 with Laemmli Sample Buffer (Bio-Rad 
Laboratories, CA, USA) and boiled for 4 minutes. 200 L of sample was run on a 4% 
stacking, and 10% separating sodium doecyl sulphate polyacrylamide gel (29:1 
ratio of acrylamide/bis) using a mini-Protean II Electrophoresis Cell (Bio-Rad 
53 
 
Laboratories) at 200 Volts for approximately 45 minutes. The separated proteins 
were transferred onto a 0.45m nitrocellulose membrane (Bio-Rad Laboratories) 
at 20 Volts for 20 minutes using a Trans-Blot Semi-Dry Transfer Cell (Bio-Rad 
Laboratories). The Membrane was blocked for 1-2 hours at room temperature on a 
rocker with a 5% blotting grade non-fat dry milk blocker (Bio-Rad Laboratories) in 
PBST. After blocking, the membrane was assembled into a mini protean II multi-
screen apparatus (Bio-Rad Laboratories). Mouse serum was diluted as indicated, in 
our 5% milk in PBST solution, and 400 L of the sample dilution were run in each 
lane. The membrane was incubated overnight at 4 C on a rocker. The membrane 
was washed six times for five minutes with PBST. The membrane was incubated 
with horseradish peroxidase-conjugated goat anti-mouse IgG1 or IgG2a (Southern 
Biotechnology Associates Inc., AL, USA) at a dilution of 1:5000 in our 5% milk in 
PBST blocking solution for 1 hour at room temperature with constant rocking. The 
membrane was removed from the multi-screen apparatus and washed four times 
for fifteen minutes with PBST. The membrane was developed using Immun-StarTM 
HRP (horseradish peroxidase) (Bio-Rad Laboratories) chemiluminescence kit as per 
the manufacturer’s instructions. The membrane was wrapped in clear plastic and 
exposed to BioMax Light Film (Kodak). Note: The procedure for western blots using 
fluorescence detection method is the same as those used for detection using 
chemiluminescence with a few minor exceptions. To decrease background blotted 
nitrocellulose membranes are blocked in PBS + 5% non-fat dry milk (Bio-Rad) 
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without the addition of tween. Furthermore we utilize secondary antibodies 
conjugated with either IRDye 800TM conjugated goat anti-mouse IgG1 (Rockland 
Immunochemicals, Gilbertsville, PA, USA) and Alexa-Fluor 680 conjucated goat 
anti-mouse IgG2a (Invitrogen) antibodies. Bands were visualized using the Licor 
Odyssey Imaging System (Licor, Lincoin, NE, USA).   
3.10 An enzyme-linked immunoassay for the detection of IgG1 and IgG2a 
antibodies specific for the L5178Y tumor P815 antigen 
3.10.1 L5178Y antigen 
L5178Y cells were harvested from in-vitro culture, washed 4 times in sterile PBS 
and resuspended at 3.3 x 107cells/ml. The cell suspension was freeze/thawed, and 
sonicated for 24 cycles on ice using a Branson Sonifer 450 (Branson, Danbury, CT, 
USA) set at 50% duty cycle. When required, the soluble and insoluble fractions 
were separated by spinning the resulting suspension for 30 minutes at a 20 000 
RCF. The soluble fraction was collected, and the insoluble fraction was re-
suspended in an equivalent volume of fresh PBS (sonicated 3-4 times to resuspend 
the pellet). The L5178Y antigen was stored at -20C until use.  
3.10.2 Enzyme-linked immunosorbant assay 
96 well high protein binding polystyrene Immuno-Maxisorp Plates (NUNC, 
Denmark) were coated overnight at 4 C with an equivalent of 3.33x106 freeze-
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thawed L5178Y cells per well in PBS. Plates were washed twice with 200 L PBST 
per well, and blocked for 2 hours at 37° C with 200 L of PBS supplemented with 
10% heat inactivated calf serum (Gibco Laboratories, Grand Island, NY, USA). Plates 
were washed twice with 200 L PBST per well. Serum samples were diluted in 1/50 
in PBS supplemented with 10% calf serum, and two-fold serial dilutions of the sera 
were performed in a 96 well low protein binding polyethylene plates (NUNC). Sera 
dilutions were transferred to the Immuno-Maxisorp test plate, and was incubated 
for 2 hours at 37 C. Test plates were washed six times with PBST, and 100 L of 
horseradish peroxidase-conjugated goat anti-mouse IgG1 or IgG2a (Southern 
Biotechnology Associates Inc., AL, USA) was added in each well of the test plate at 
a dilution of 1:5000 in PBS supplemented with 10% calf sera. The plate was 
incubated at 37° C for one hour then washed 6 times with PBST. 100 L ATBS (2,2`-
azino-di (3-ethyl-benzthiazoline-6-sulfonate)) 1-component microwell peroxidase 
substrate (Kirkegaard & Perry Laboratories, Inc, Gaithersburg, MD, USA) was added 
to each well. The test plate was incubated for 20 minutes at room temperature in 
the dark. The test plate was read using an E-max microplate reader (Molecular 
Devices Corporation, Sunnyvale, CA, USA) at a wavelength of 405 nm, and resulting 
data was collected and analyzed using the Softmax Professional version 2.2.2 
(Molecular Devices Corporation) computer program.  The signal from serum from 
naïve mice is never above the values obtained from our conjugate blank control 
wells (an adsorbance of 0.065). I assigned the serum titer using a cutoff value of 
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this assay as being an adsorbance two times above the value obtained when using 
sera from a non-immunized animal.  
3.11 Monoclonal antibody production, and purification 
Antibodies were generated as ascities in mice. Mice greater than 12 weeks of age 
were injected with 0.5 ml of either pristine (Sigma, St Louis, MO, USA), or 
Incomplete Freund’s Adjuvant (Difco Laboratories, Detroit, MI, USA) into their 
peritoneum. One to two weeks later, mice were given 1500 Rads of gamma 
irradiation and were implanted with 107 hybridoma cells into their peritoneum in 
0.5 ml sterile PBS. Roughly 7 days later the resulting ascities was collected by 
aspirating their peritoneum. The antibodies were purified using a T-GelTM 
Purification Kit (Pierce Biotechnology Inc., Rockford, IL, USA), and antibody 
concentration was determined using a BCATM Protein Assay Kit (Pierce 
Biotechnology Inc.) as per the instructions of the respective manufacturers.  
3.12 Cell proliferation assays 
To determine if the presence of neutralizing anti-IL-4, or control antibodies 
decreased the rate of in-vitro growth of P815 cells, we plated 104 P815 cells/well of 
a 96 well plate, and incubated the cells with varying concentrations of antibodies 
(11B11 or GK1.5 clonotypes) for 24 hours. Cells were labeled with 0.5 Ci 3H 
thymidine for the last four hours of culture. Radiolabeled DNA was harvested using 
a PHDTM Cell Harvester (Cambridge Technology INC, Lexington, MA, USA note: this 
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product is currently produced by Brandel INC, Gaithersburg, MD, USA) onto glass 
fiber filter strips (Brandel Inc) which are placed into 6 ml liquid scintillation vials 
(Wheaton Science Products, Millville, NJ, USA). The samples were air-dried 
overnight, and 4 ml of syntillation fluid, Touline supplemented with 4 g/L omniflour 
(Packard Instrument Company INC, Meriden, CT, USA), was added to each tube. 
Radioactivity of the incorporated radio-isotope was assessed using a Beckman 
LS5000TD syntillation counter(Beckman Instruments, Fullerton, CA, USA).  
3.13 Statistical analysis 
Unless otherwise indicated the error bars on all graphs are representative of 
the standard deviation of the number of spots counted in three assay wells in the 
ELISPOT assay.  
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4 Results 
4.1 Generation of a protective anti-P815 Immune Response 
I have utilized a priming strategy by which we can consistently render DBA/2J mice 
resistant to a normally lethal challenge of the P815 tumor. Mice are primed by 
injecting 105 P815 cells subcutaneously into their right hind footpad. These mice 
can resist a subsequent, normally lethal, challenge of 105 to 2x106 P815 cells given 
intradermally into their belly, given a minimum of two weeks post priming (Figure 
1). This priming strategy has been performed on more than 200 mice, and 
consistently renders over 80% of animals resistant to a normally lethal challenge of 
the P815 tumor. The efficacy of protection generated by this protocol remains 
stable for one year.  
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Figure 1: Rendering mice resistant to a normally lethal P815 challenge. 
A) The mouse was given no pre-treatment, while the mouse shown in B) was given 
105 P815 cells subcutaneously into its right hind footpad 14 days prior to both mice 
being challenged with 105 P815 cells intradermally into their abdomen. This photo 
was taken 19 days post challenge. C) DBA/2J mice were injected with 105 P815 cells 
subcutaneously into their right hind footpad (fp). 15 days later, appropriate mice 
were implanted with 105 P815 cells injected intradermally (id) into their abdomen. 
Percent survival was assessed over a period of 40 days. Seven of the eight mice 
primed with the P815 resisted the challenge.  
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4.2 Standardization of the ELISPOT assay for the detection of 
P815-dependent INF and IL-4 secreting cells 
A protocol was established to characterize the Th1/Th2 nature of the anti-tumor 
immune response being mounted against the P815 cells by enumerating P815-
dependent cytokine secreting spleen cells in a modified ELISPOT assay. Several 
interdependent difficulties were encountered in my attempts to detect P815-
dependent cytokine secreting cells. The first major difficulty is that P815 rapidly 
metastasizes to the spleen of mice. To assess the antigen-dependent cytokine 
production by splenocytes one must find a protocol to remove the majority of 
P815 cells contaminating the spleen preparations. Fortunately, I found one can 
remove P815 cells which have metastasized to the spleen by running our cell 
preparations through a nylon wool column. Another difficulty I encountered was 
determining an appropriate antigen preparation to utilize in the P815 ELISPOT 
assay. I began by using freeze-thawed P815 cells as the antigenic source; however, 
it became clear that such an antigen preparation failed to induce any antigen 
dependent cytokine secretion while gamma-irradiated or mytomycin-C treated 
antigen preparations were able to elicit antigen-dependent cytokine secretion by  
spleen cells from P815-primed animals (Figure 2).  
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Figure 2: Intact P815 antigen is required for optimal detection of tumor-
dependent INF secretion by primed spleen cells. 
DBA/2J mice were primed ten days prior with 105 P815 cells intradermally into 
their abdomen. Spleen cells were purified on nylon wool columns to remove any 
P815 cells that have metastasized to the spleen. The non-adherent effluent cells 
were plated in the ELISPOT assay at an equivalent of 1.5x106 cells per well. 
Splenocytes from a naïve DBA/2J mouse were added as APC to give an equivalent 
of 2x106 total spleen cells per well. An equivalent of 5x105 P815 cells were used as 
antigen in each well. Number of spots detected using A) freeze-thawed antigen, B) 
gamma irradiated (approximately 20,000 Rads) P815 cells, C) P815 cells treated 
with mitomycin C (50µg MitoC/106 tumor cells) at 37° C for one hour prior to 
utilization as antigen in our ELISPOT assay. Data is graphed as tumor dependent 
INF production per 2x106 primed spleen cells.  
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 Furthermore, I was able to demonstrate this freeze-thawed antigen not only 
failed to induce, but also inhibited the cytokine production by primed spleen cells 
when co-cultured with gamma-irradiated P815 cells (Figure 3). It is very likely that 
disrupting the membrane of P815 cells, which is a mastocytoma, releases a number 
of bioactive molecules toxic to cells in culture. Based upon these observations, I 
began to use whole tumor cell as antigen in the ELISPOT assay.  
It was observed that a relatively small proportion of P815 cells (0.04-0.14%) 
secrete IL-4 during the eight hour restimulation process of the ELISPOT assay. 
Although relatively infrequent, this IL-4 secretion by P815 cells used as antigen can 
effectively mask the detection of P815-dependent IL-4 secretion by primed spleen 
cells. Fortunately, I was able to show that treating P815 cells with either Mitomycin 
C, or gamma-irradiation (~20 000 Rads) prevented IL-4 secretion by P815 cells, 
allowing me to use them as the antigenic source in the ELISPOT assay (Figure 4).  
To determine the optimal antigen concentration for the detection of P815-
dependent IL-4 and INF secreting cells a range of gamma-irradiated P815 antigen 
were given per well together with a constant number of primed spleen cells. As 
shown in Figure 5, 5x105 gamma-irradiated P815 cells proved to be optimal 
number for the detection of tumor-dependent cytokine secretion by spleen cells. 
 
 
 
63 
 
 
 
 
0 10 20 30 40 50
IL-4
5x105  -Irradiated P815
5x105  -Irradiated + 105 Freeze-Thawed P815
5x105  -Irradiated + 106 Freeze-Thawed P815
5x105  -Irradiated + 107 Freeze-Thawed P815
107 Freeze-Thawed P815
106 Freeze-Thawed P815
105 Freeze-Thawed P815
P815-Dependent Cytokine Secreting Cells per 2x106 Spleen Cells
107 Freeze-Thawed P815 + 5x105 -irradiated P815
106 Freeze-Thawed P815 + 5x105 -i radiated P815
105 Freeze-Thawed P815 + 5x105 -i radiated P815
5x105 -irradiated P815
107Freeze-Thawed P815
106 Freeze-Thawed P815
105 Freeze-Thawed P815
P815-Dependent Cytokine Secreting Cells 
per 2x106 Spleen Cells  
 
Figure 3: The presence of freeze-thawed P815 antigen inhibits the generation of 
spots from primed spleen cells stimulated with gamma-irradiated P815 cells. 
Mice were implanted with 105 P815 intradermally into their belly. On Day 10 of 
tumor growth spleens were harvested, and prepared as previously described. 
Primed spleen cells were plated in the ELISPOT assay with normal spleen as a 
source of APC (see legend to Figure 3), and various amounts of freeze-thawed  
P815 cells were added to a constant number of gamma-irradiated (20 000 Rads) 
P815 cells. P815-dependent IL-4 secretion was enumerated.  
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Figure 4: Inhibition of endogenous IL-4 secretion by P815 cells. 
A) The effect of different treatments of P815 cells on IL-4 spot formation. P815 
cells were treated with either mitomycin C (50µg Mito-C/106 tumor cells for one 
hour at 37°) or given 20000 Rads of gamma irradiation on their ability to produce 
spots corresponding to IL-4 producing cells. B) Determination of the dose of 
gamma irradiation required to inhibit secretion of IL-4 by P815 cells. Non- 
irradiated or P815 cells given different doses of gamma-irradiation were plated in 
our ELISPOT assay at 5x105 cells/well to determine their ability to secrete IL-4 
during our standard 8 hour ELISPOT incubation. 
 
A
B
0
100
200
No Treatment Mito-C -Irradiation
IL
-4
 S
p
o
ts
 p
er
 5
x1
0
5
P
8
1
5
 C
e
lls
0
20
00
60
00
10
00
0
18
00
0
30
00
0
0
250
500
750
IL
-4
 S
p
o
ts
 p
er
 5
x1
0
5
P
8
1
5
 C
e
lls
Number of Rads
65 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5: Assessing the optimal antigen concentration for the detection of P815-
dependent INF and IL-4 producing cells by the ELISPOT assay. 
Mice were primed in the hind footpad with 105 P815 40 days prior to challenge 
with 2x106 P815 intradermally into their belly. ELISPOT was performed 20 days 
after challenge.  Spleen cells from three mice were pooled and tumor-dependent 
cytokine production was determined using the ELISPOT assay as previously 
described.  Irradiated P815 cells (20000 Rads) were used as a source of antigen and 
were plated at varying dilutions. Antigen dependent INF and IL-4 production is 
depicted as antigen dependent spots per well.  
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Linearity of the spots being detected by the ELISPOT assay is essential to ensure 
the tumor-dependent spots being generated are due only to the primed cells 
added to our assay. To assess whether the assay had this desirable feature, I 
diluted the primed cells, while keeping all other variables in our assay constant by 
adding feeder cells from non-immunized mice. As shown in Figure 6, both the 
number of IL-4 and INF producing cells detected by the assay depend on the 
number of primed spleen cells plated. Based on these experimental findings, we 
can conclude that the ELISPOT assay has been standardized and optimized for the 
detection of P815-dependent IL-4 and INF secreting cells. 
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Figure 6: Linearity of the detection of P815-dependent INF and IL-4 producing 
cells is directly related to the number of primed spleen cells plated in the ELISPOT 
assay. 
DBA/2J mice were injected with 105 P815 cells intradermally into their abdomen. 
16 days after inplantation, spleens from 2 DBA/2J mice were pooled and prepared 
as previously described.  Different numbers of primed spleen cells were plated in 
the ELISPOT assay and complemented with additional spleen cells from normal 
mice to keep the total cell number constant at 2x106 cells per well. 5x105 gamma-
irradiated (20000 rads) P815 cells as antigen were added to appropriate wells. 
Antigen-dependent INF and IL-4 spots were enumerated. 
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4.3 Standardization of the L5178Y ELISPOT assay 
Optimizing the detection of L5178Y-specific cytokine secreting cells in the 
ELISPOT assay was significantly less complicated than for P815-specific cells. I have 
observed that L5178Y cells do not endogenously produce either INF or IL-4 and, 
most importantly, this tumor cell line does not readily metastasize to the spleen in 
mice rendered resistant, eliminating many potential problems of significant 
antigen carry-over in the ELISPOT assay. I have observed mice bearing large tumors 
have a significant tumor burden in their spleen (Figure 7). This late metastasis to 
the spleen of mice with progressively growing tumors has not proven itself to be an 
obstacle in our experimental system. 
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Figure 7: Metastasis of L5178Y cells to the spleen of mice bearing large, 
progressively growing tumors. 
Spleen cells from mice with tumors that are either progressing, regressing or from 
mice having successfully induced complete tumor regression at the site of tumor 
challenge were assessed for tumor burden in their spleen. Spleen cells were plated 
in a 96 well plate at an original concentration of 2x107 cells per well in triplicate, 
and a 1/3 dilution series was performed. The dilution factor plotted corresponds to 
the lowest dilution not to support tumor growth.  
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I wished to explore the use of intact tumor cells as a source of antigen in the 
ELISPOT assay to enumerate L5178Y-specific cytokine producing cells. To prevent 
the L5178Y cells from dividing in the ELISPOT assay, they were given a dose of 
gamma irradiation (5000 rads) I determined would prevent their division. As with 
our P815 ELISPOT assay, I determined the optimal concentration of gamma- 
irradiated L5178Y cells for the detection of tumor-dependent cytokine secreting 
cells by plating a constant number of primed cells in the presence of differing 
numbers of gamma-irradiated L5178Y cells (Figure 8). In this manner, I determined 
1x105 gamma-irradiated L5178Y cells was the optimal concentration of antigen for 
use in our ELISPOT assay. To assess whether the number of tumor-specific spots 
generated in our ELISPOT assay were linearly dependent on the number of 
sensitized cells plated, I diluted the primed cells while keeping all other variables in 
our assay constant. As is shown in Figure 9, the assay is linear for INF and IL-4 
producing cells. Based upon these observations, we consider the ELISPOT assay is 
optimized for the detection of L5178Y-dependent INFγ and IL-4 secreting cells. 
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Figure 8: Assessing the optimal number of L5178Y cells required for stimulating 
tumor primed spleen cells for the detection of tumor-dependent INF-producing 
cells in the ELISPOT assay. 
Mice were implanted on day 0 with 106 L5178Y cells intradermally into their belly. 
On day 18, the spleens of three mice, whose tumor had begun to regress, were 
pooled. Spleen cells were plated at 106 cells per well and varying numbers of 
gamma-irradiated (5000 rads) L5178Y cells were added as a source of antigen, and 
the number of antigen-dependent spots was assessed.    
5
0
0
0
0
0
0
2
5
0
0
0
0
1
2
5
0
0
0
6
2
5
0
0
3
1
2
5
0
1
5
6
2
5
7
8
1
2
3
9
0
6
1
9
5
3
9
7
7
4
8
8
2
4
4
1
2
2
6
1
3
1 00
10
20
30
40
50
60
70
80
IFN
Number of gamma-irradiated L5178Y cells per well
N
u
m
b
e
r 
o
f 
L
5
1
7
8
Y
-D
e
p
e
n
d
e
n
t 
S
p
o
ts
 p
e
r 
w
e
ll
72 
 
 
Number of Primed Spleen 
Cells/Well (x 2x105)
L5
1
7
8
Y
-D
e
p
en
d
e
n
t 
Sp
o
ts
 p
er
 w
el
l
 
Figure 9: The number of L5178Y-dependent INF and IL-4 spot forming cells 
detected depends linearly on the number of sensitized spleen cells plated in the 
ELISPOT.  
Top panel: Mice that had previously rejected a dose of 103 L5178Y tumor cells were 
challenged with 106 L5178Y cells. 20 days after challenge the spleens of two mice 
were pooled and used as a source of sensitized cells for the experiment. Bottom 
panel:  the spleens of two mice, implanted 20 days prior to assay with 106 L5178Y 
cells, were pooled. Spleen cells were plated into our ELISPOT assay at various 
dilutions, using spleen cells from naïve animals to keep the total cell number 
constant at 2x106 cells per well 5x105 gamma-irradiated (5000 Rads) P815 antigen 
was added to appropriate wells. Antigen-dependent INF and IL-4 spots were 
enumerated. 
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4.4 Immune correlates of tumor progression or regression  
4.4.1 Correlates of protection in the P815 mastocytoma system  
Even with the optimized P815 ELISPOT assay it has proven to be relatively difficult 
to consistently detect P815-dependent cytokine secretion. I believe such variability 
is primarily due to different rates of tumor growth and the associated variable 
kinetics in the anti-tumor immune response. Observations illustrating these 
statements will be described in subsequent sections. Despite some variability in 
detecting immune responses in the optimized ELISPOT assay, its use has allowed 
me to assess the Th1/Th2 nature of anti-P815 immune response in some mice with 
progressively growing P815 tumors and in some mice rejecting the tumor. As 
shown in Figure 10, progressive tumor growth is associated with a mixed INF/IL-4 
response, while protected mice mount a predominant, sustained INF response to 
P815 antigens. 
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Figure 10: Lymphocytes from mice rendered resistant to P815 secrete INF, while 
mice suffering from progressive tumor growth secrete mixed IL-4 and INF 
cytokines in response to tumor antigens. 
A) Mice were implanted with 2x106 P815 cells intradermally on Day 0. Two mice 
were assayed at each time point for enumeration of tumor-specific INF and IL-4 
producing cells by ELISPOT. B) Mice were rendered resistant to P815 challenge by 
priming mice with 105 P815 cells into their hind footpad, and challenged 14 days 
later with 105 P815 cells intradermally into their belly. The immune response was 
assessed 30 days post challenge. Results are presented as tumor-dependent INF 
or IL-4 spots per 2x106 immune splenocytes.  
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4.4.1.1 Surface marker phenotype of P815-dependent INFγ and IL-4 secreting 
cells  
To determine the cells responsible for P815-dependent spot formation in the 
ELISPOT assay, we used MACS sorting to purify Thy1.2+, CD8+ and CD4+ cells. 
Purity of the respective populations was assessed by flow cytometry, and 
determined to be greater than 90% (Figure 11 A). We observed, using these 
purified cells in our ELISPOT assay that cytokine-producing cells were 
predominately Thy1.2 positive cells. IL-4 was secreted by CD4+ cells, while most 
INF  secreting cells were CD8+ T cells (Figure 11 B and C).    
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Figure 11: Phenotype of cells producing P815-dependent INF and IL-4 spots in 
the ELISPOT assay. 
 A) Assessment of the purity of spleen populations obtained utilizing midiMACS as 
per manufacturer’s standard protocol for Thy1.2+, CD8+ and CD4+ T cells. B) Mice 
were rendered resistant to P815 challenge by first priming 4 months prior with 105 
P815 cells into their hind footpads, and challenged intradermally with 2x106 P815 
cells into their belly. Ten days later, three mice were killed and their spleens were 
harvested, pooled and used to assess the phenotype of cells responsible for spot 
formation indicating INF and IL-4 cytokine producing cells. C) Three mice were 
given 106 P815 cells intradermally into their belly 10 days prior to sacrifice and 
their spleen cells were harvested and pooled. The spleen populations were 
fractionated using midi-Macs for Thy1.2+, CD4+ and CD8+ positive and negative 
ELISPOT assay. Figure is representative of two independent experiments.  
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4.4.2 Correlates of protection in the L5178Y lymphoma system 
The variability in the detection of P815-dependent cytokine secreting cells are not 
mirrored in the L5178Y system. When we first received the L5178Y cell line from 
Dr. R.J. North, we observed some initial difficulties in inducing progressive tumor 
growth. Initially, the majority of mice given what was reported to be a normally 
lethal tumor challenge, 106 cells implanted i.d., spontaneously resolved their 
tumors. I was able to increase the tumorogenicity of this cell line by passaging the 
cells in-vivo a number of times. The initial inability to reliably establish progressive 
tumor growth was a set back, but allowed us to compare the Th1/Th2 nature of 
the immunity being generated in mice challenged with the same tumor dose but 
spontaneously rejecting the tumor or suffering from progressive tumor growth. 
DBA mice were challenged with 106 L5178Y tumor cells i.d. thirty-three days after 
implantation 9 out of 12 mice had undergone complete tumor regression. An 
ELISPOT assay was performed to compare the immune responses between these 
two groups of mice. The results essentially mirror those obtained using the P815 
tumor. A significant predominance of IL-4 was observed in mice suffering from 
progressive tumor growth, while INF dominates the immune response in mice 
that had successfully contained the tumor (Figure 12). As with the P815 system we 
assessed the cell populations responsible for the cytokines produced in response to 
tumor antigens. 
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Figure 12: Resistance to the L5178Y tumor is associated with antigen-dependent 
INF production while tumor progression is associated with IL-4 production. 
 
DBA mice were challenged with 106 L5178Y tumor cells intradermally into their 
belly. Three of twenty mice developed progressive tumor growth. We assessed 33 
days post-challenge the types of anti-tumor immune responses associated with 
mice suffering from progressive tumor growth and in those mice that rejected the 
tumor. AM refers to aged matched control.  
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As shown in Figure 13, IL-4 is produced by CD4+ T cells along with non-T cells, while 
the INF is produced by both CD4+ and CD8+ T cells in response to L5178Y 
antigens. 
4.5 Modulation of MHC Expression on P815 and L5178Y tumor cells  
We have been considering the role of CD4+ T cells as an indirect marker of the 
critical effector cells that attack the tumor, assuming they themselves have no 
direct effect on the tumor. They could act directly on tumors if the tumors bore 
class II MHC expression. We therefore assessed the expression of Class I and II 
MHC molecules on the surface of the P815 and L5178Y cell lines. Figure 14 
demonstrates that neither P815 nor L5178Y cell lines express MHC class II 
molecules on their surface. Furthermore, we were unable to induce MHC class II 
expression on either tumor after treatment with INF for 24 hours in culture.  
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Figure 13: Phenotype of tumor-specific cells producing INF and IL-4 cytokines 
from mice rendered resistant to, or suffering progressive, L5178Y tumor growth. 
A) Mice suffering progressive L5178Y tumor growth, after being implanted with 106 
L5178Y cells intradermally 19 days prior harvest. B) Mice rendered resistant to 
L5178Y tumor growth after priming intradermally with 103 L5178Y cells 6 months, 
and being challenged 1 month prior to the assay with 106 L5178Y cells 
intradermally. The spleen preparation was separated into different cell populations 
using midi-Macs. IL-4 and INF secretion by the resulting fractions was assessed by 
the ELISPOT assay. Figure is representative of two independent experiments. 
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Figure 14: Effect of INF treatment on MHC expression by P815 and L5178Y cells 
P815 or L5178Y cells were incubated at a cell density of 2x106 cells per well in 24 
well plates, and treated for 24 hours with either: 0, 200, 400 or 500 units/ml of 
recombinant INF. Cells were harvested, and were assessed for MHC class I and II 
expression by flow cytometry. Shaded areas represent the background 
fluorescence of unstained cells. 
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4.6  Correlation of tumor-specific antibody subclass with tumor 
protection 
Our hypothesis and results obtained using the ELISPOT assay strongly suggest 
the Th1/Th2 nature of the anti-tumor immune response correlates with tumor 
protection or progression. One goal of this line of research is to devise strategies 
by which one can assess the Th1/Th2 nature of spontaneous anti-tumor immune 
responses in human cancers, and use such observations to guide cancer treatment. 
In human cancers the primary source of lymphocytes available are from the 
peripheral blood. One can question if the Th1/Th2 nature of the peripheral 
response is characteristic of the true ‘systemic’ immune response seen in a 
secondary lymphoid tissue. Using mouse models, it is relatively easy to directly 
compare the Th1/Th2 nature of antigen-dependent immune responses in the 
spleen and peripheral blood using the ELISPOT assay. It is however likely our tumor 
systems are not a useful model in which to test such a hypothesis as it is quite 
apparent by microscopic analysis that there are many tumor cells circulating in the 
blood of animals bearing intradermal tumors. Early in my graduate studies, I had 
done a considerable amount of work using the intracellular parasite, Leishmania 
major (MHOM strain). Using such an experimental model I was able to directly 
compare the Th1/Th2 nature of the anti-parasite immune response being 
generated in the spleen as compared to lymphocytes isolated from the peripheral 
blood. The CBA/J strain of mice is known to be very resistant to infection with 
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Leishmania major; in fact, mice given a very high dose (3x108) of parasites into 
their hind foot pad show no clinical signs of disease other than some mild footpad 
swelling which spontaneously resolves. Such resistance correlates with 
predominant INF secretion by spleen cells in response to parasite antigens. 
However, when we characterize the Th1/Th2 immunity utilizing cells harvested 
from the peripheral blood from these same animals we observe an exaggeration in 
the Th2 component of the immune response (Figure 15). If such observations are 
mirrored in humans utilizing cells isolated from the peripheral blood to assess the 
Th1/Th2 nature of immunity may prove to be misleading. In this regard I began to 
assess if other methodologies could be utilized to characterize the Th1/Th2 nature 
of the anti-tumor immune response.  
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Figure 15: Exaggeration of the Th2 component of the antigen-dependent immune 
response in the peripheral blood as compared to the spleen. 
Groups of CBA/J mice were infected with varying numbers of Leishmania major 
promastigotes on day 0. Four months post infection mice were bled, and their 
spleens were harvested and immune responses assessed by the ELISPOT assay. A) 
The number of antigen-dependent INFγ and IL-4 secreting cells in the spleen (upper 
panel) and peripheral blood (middle panel). B) The ratio of Leishmania major-
dependent INFγ to IL-4 secreting cells from spleen and peripheral blood leukocytes 
is depicted. 
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In the mouse models of Mycobacterium bovis (BCG strain), and Leishmania 
major our laboratory has previously demonstrated the Th1/Th2 nature of the 
immune response can be assessed by comparing the relative abundance of 
pathogen-specific IgG1 and IgG2a antibodies in sera. High amounts of IgG1 
antibodies correlate with a response with a large Th2 component, while IgG2a 
antibodies are associated with a predominant Th1 response (Chen, Gure et al. 
1998; Bretscher, Ismail et al. 2001; Uzonna and Bretscher 2001). Based on these 
observations, I have devised protocols to assess the relative abundance of tumor-
specific IgG1 and IgG2a antibodies as a measure of the Th1/Th2 nature of our anti-
tumor immune response, and assessed whether there is a correlation of prevalent 
IgG isotypes with regards to tumor outcomes. I believe such a strategy, if 
realizable, may prove itself to be very useful in a clinical setting. 
4.7 Correlation of tumor-specific antibody subclass with tumor resistance or 
tumor progression 
I have developed a western blotting protocol to determine the predominance 
of tumor-specific IgG1 and IgG2a antibodies in the sera of animals bearing P815 
and L5178Y tumors. Exploiting this western blotting strategy I have been able to 
identify clear correlates of tumor protection or regression by assessing the relative 
abundance of IgG1 and IgG2a antibodies to tumor antigens. 
It is important to note that the variability with regards to detecting P815-
dependent cytokine producing cells in the ELISPOT assay is not mirrored by 
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variability in our western blotting assay. This simple protocol very consistently 
detects anti-P815 antibodies beyond those present in P815 non-exposed mice. I 
compared the relative abundance of tumor-specific IgG1 and IgG2a antibodies in 
mice rendered resistant as compared to mice suffering from progressive P815 
tumor growth. Mice rendered resistant have a predominance of P815-specific 
IgG2a antibodies, while mice suffering progressive P815 tumor growth have a 
predominance of tumor-specific IgG1 antibodies (Figures 16, 17 and 18). These 
observations correlate with the cytokine producing cells data obtained utilizing the 
ELISPOT assay. 
 Using this western blotting methodology, we were able to demonstrate 
that the priming strategy, which renders DBA/2J mice resistant to a normally lethal 
tumor challenge, induces a stable Th1 response to tumor antigens. While rare in 
occurrence, our priming strategy occasionally results in progressive tumor growth 
in the footpad. We were able to demonstrate such progressive tumor growth 
correlates with the development of tumor-specific IgG1 antibodies (Figure 15B). 
Groups of mice implanted with the same lethal dose of P815 cells do not 
always have the same rate of tumor growth. Using the western blotting protocol 
we have been able to longitudinally indirectly assess the Th1/Th2 nature of the 
immune response being generated in animals in which the rate of P815 growth is 
markedly different. As shown in Figure 18, one can observe an increase in the 
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relative amount of IgG2a antibodies in the animal with a more slowly progressing 
P815 tumor as compared to a mouse with a P815 tumor progressing more rapidly. 
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Figure 16: Effective protection against P815 is associated with predominant IgG2a 
antibody production against the tumor.  
105 P815 cells were implanted into the hind foot pad of DBA mice on Day 0. Mice 
were serially bled over the course of 28 days, and the relative abundance of P815-
specific IgG1 and IgG2a antibodies were assessed by western blot. Panel A 
represents a mouse in which there was no evident tumor growth in the foot pad, 
and which resisted a subsequent normally lethal P815 tumor challenge on Day 28. 
Panel B represents a rare occasion in which the mouse suffers from progressive 
P815 growth in its footpad.  
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Figure 17: Mice rendered resistant to a normally lethal dose of P815 is 
associated with predominant Th1-type immunity, as assessed by western blot. 
Mice were implanted with 105 P815 cells (s.c.) into their hind footpad on Day 0, 
and challenged with 105 P815 (i.d.) into their belly on Day 35. Mice were bled 
weekly, and the relative abundance of P815-specific antibodies was assessed by 
western blot with dilution of sera of 1/100, 1/200 and 1/400.  Similar experiments 
have been performed on greater than 40 individual mice with animals falling into 
one of the three representative groups depicted. The vast majorities of mice are 
successfully vaccinated and are represented in the top panel showing an initial 
decrease in the abundance of antibodies, and then a sustained predominance of 
tumor-specific IgG2a antibodies. The middle panel represents animals with very 
little or no detectable antibodies. Although more rare in occurrence, it could 
possibly demonstrate a very strong cell mediated immunity in the absence of 
detectable tumor-specific antibodies. The bottom panel is the rarest of the three 
occurrences, where the tumor initially grows out after challenge, and subsequently 
resolves. This initial outgrowth is associated with tumor-specific IgG1 antibodies, 
and subsequent resolution correlates with a disappearance of these IgG1, and 
maintenance of IgG2a antibodies specific for tumor antigens.  
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Figure 18: Differing rates of P815 growth is associated with differing relative 
abundance of tumor-specific IgG1 and IgG2a antibodies. 
DBA mice were implanted with 105 P815 intradermally into their abdomen on Day 
0. The rate of tumor growth was assessed as was the relative abundance of tumor-
specific IgG1 and IgG2a antibodies by western blot. As assessed with serum diluted 
100 fold. Although individual mice are depicted, the results are indicative of 
greater than ten mice. 
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At present, there is no technique by which one can predict the reemergence of 
a cancer. The observations presented within this thesis suggest tumor 
reoccurrence might often be associated with the development of Th2 responses 
against tumor antigens. In this light one could utilize this western blotting strategy 
to assess this immune failure, and perhaps predict the reemergence of a tumor 
before this becomes apparent in terms of a mouse’s health. In a very rare 
occurrence, I observed the spontaneous regression of a P815 tumor in a mouse 
implanted with a normally lethal dose of the tumor. This mouse showed no signs of 
tumor for 10 days, but the tumor reemerged at the site of implantation and grew 
progressively. The mouse was bled over the 10 week course of tumor growth, and 
the Th1/Th2 nature of the anti-tumor immune response was indirectly assessed by 
our western blotting protocol. I was able to demonstrate that regression of the 
primary tumor is associated with the predominance of IgG2a antibodies to the 
tumor antigen. Tumor reemergence and subsequent progressive growth is 
associated with a very dramatic switch from a predominant IgG2a response to a 
mixed IgG1/IgG2a, and later to a predominant IgG1 response (Figure 19). Although 
this represents analysis of a single mouse undergoing a very uncommon protracted 
rate of P815 tumor growth, it very clearly demonstrates the utility of our western 
blotting method to assess immune failure.  
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Figure 19: Regression of P815 and subsequent progressive P815 tumor growth is 
associated with a switch in the relative predominance of tumor-specific IgG1 and 
IgG2a antibodies. 
The mouse was implanted with 105 P815 cells on Day 0. The P815 tumor 
spontaneously resolved, and subsequently reappeared and grew progressively at 
the site of injection. The mouse was bled over a period of 10 weeks and the 
relative predominance of P815-specific IgG1 and IgG2a antibodies was assessed by 
western blot. 
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4.8 Correlation of L5178Y-specific antibody subclass and tumor 
progression and regression 
I failed in my attempts to devise an EIA strategy to detect anti-P815 antibodies; 
however, I have been able to develop an EIA protocol to assess the relative 
abundance of L5178Y-specific IgG1 and IgG2a antibodies. I believe my ability to  
devise an EIA protocol for the detection of L5178Y-specific antibodies,  and inability 
for the detection of P815-specific antibodies is due to the fact that antibodies 
generated in response to the P815 tumor antigens are directed against soluble 
proteins, whereas mice bearing L5178Y tumors generate antibodies against both 
soluble and insoluble L5178Y proteins (Figure 20). As such, some of the tumor 
associated L5178Y antigens may simply bind plastic better than those from P815.   
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Figure 20: The ability of antibodies from P815 or L5178Y tumor bearing mice to 
recognize soluble and insoluble components of their respective tumors.   
Groups of five mice were primed with either 106 L5178Y or 105 P815 cells 
intradermally were bled three weeks later. The ability of tumor-specific antibodies 
to recognize the soluble or insoluble components of their respective tumors was 
assessed by western blot. Carried out with sera diluted 100 fold.  
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Utilizing this EIA technique to assess the relative abundance of L5178Y-
specific IgG1 and IgG2a antibodies, I attempted to ascertain if the same correlates 
we observed with the P815 tumor also apply to mice bearing an L5178Y tumor. As 
previously discussed, there are instances where mice within the same 
experimental group either suffer progressive L5178Y tumor growth, or 
spontaneously reject the tumor. As shown in Figure 21, our EIA protocol has 
allowed us to demonstrate a clear correlation between a predominance of IgG2a 
antibodies with tumor regression, and between a mixed IgG1/IgG2a or a 
predominant IgG1 antibody response to L5178Y antigens and tumor progression. 
These results demonstrate the relatively dynamic nature of the anti-L5178Y 
immune response. The ratio of L5178Y-specific IgG2a to IgG1 antibodies can 
change over time. This ratio correlates well with the rate of tumor growth. Mice 
with spontaneously regressing tumors maintain a relatively high ratio of tumor-
specific IgG2a:IgG1 antibodies, while in mice with progressively growing tumors 
this ratio can initially be high, but subsequently decrease as the tumor 
progressively grows. These results further suggest that one can utilize this strategy 
to monitor anti-tumor immune responses, and predict whether a tumor will be 
contained, or will grow progressively.  
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Figure 21: Relative abundance of tumor-specific IgG1 and IgG2a antibodies in 
mice with either progressive or spontaneously regressing L5178Y tumors. 
DBA mice were implanted with 2x106 L5178Y tumor cells on Day 0. Six out of 
twenty mice suffered from progressive tumor growth. Mice were serially bled over 
the course of tumor growth, and the ratio of L5178Y-specific IgG2a to IgG1 
antibodies was assessed by EIA for four mice rejecting the tumor (Panel A) and four 
mice showing progressive tumor growth (Panel B). Naïve mice consistently have no 
detectable anti-L5178Y antibodies in their sera. 
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4.9 Low doses of tumor correlate with the generation of 
protective immunity. 
Our observations demonstrate that the generation of Th1 immunity against 
tumor antigens correlates with protection. In many experimental models the 
administration of low doses of protein antigens, complex non-replicating antigens, 
and slowly replicating microorganisms results in the generation of stable antigen-
specific Th1 responses (Bretscher, Ismail et al. 2001). In view of this generalization, 
I gave decreasing doses of tumor antigens and assessed the effect on both tumor 
outcome, and correlated this outcome with the relative predominance of L5178Y-
specific IgG2a and IgG1 antibodies. Mice were implanted with doses of L5178Y 
tumor ranging from 104 to 106 tumor cells. Mice given the high, and intermediate 
doses of tumor cells suffered progressive tumor growth, which correlates with the 
generation of anti-L5178Y IgG antibody with a low IgG2a:IgG1 ratio. Mice given low 
doses of L5178Y tumor spontaneously regressed their tumors, and were 
subsequently resistant to a normally lethal challenge of the L5178Y tumor. This 
protective anti-tumor immune response correlates with a high ratio of IgG2a:IgG1 
antibodies against the L5178Y tumor (Figure 22). 
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Figure 22: Administration of low doses of L5178Y tumor cells is associated with 
tumor regression, and an increase in the relative predominance of tumor-specific 
IgG2a antibodies. 
Mice were implanted with varying doses of L5178Y cells intradermally into their 
belly on Day 0. The rate of tumor outgrowth was assessed, and the IgG2a:IgG1 
ratio of L5178Y-specific antibodies was assessed by EIA at 14 days after tumor 
challenge. 
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I have also utilized the western blotting strategy to assess the relative 
predominance of L5178Y-specific IgG1 and IgG2a antibodies. These results 
obtained by western blot correlate very well to those obtained by EIA. Progressive 
growth of the L5178Y tumor is associated with a predominance of tumor-specific 
IgG1 antibodies. Our results also demonstrate an increase in the relative 
abundance of L5178Y-specific IgG2a antibodies in mice suffering from a more 
protracted rate of tumor growth (Figures 23 and 24). Mice undergoing 
spontaneous tumor regression have an initial mixed response to tumor antigens, 
which subsequently is replaced with a predominant IgG2a antibody response 
against L5178Y tumor (Figure 25).    
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Figure 23: Rapid progression of the L5178Y tumor correlates with an increase in 
tumor-specific IgG1 antibodies as compared to the isotypes of antibodies present 
in the serum of animals with prolonged survival. 
Mice were implanted with 1.2x106 L5178Y tumor cells intradermally on Day 0. 
The rate of tumor growth was assessed along with the development of tumor-
specific IgG1 and IgG2a antibodies by western blot over the course of tumor 
growth. 
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Figure 24: Prolonged L5178Y tumor growth is associated with an increase in 
tumor-specific IgG2a antibodies. 
The mouse was implanted with 106 L5178Y tumor cells intradermally on Day 0. 
The rate of tumor growth was assessed along with the development of tumor-
specific IgG1 and IgG2a antibodies by western blot over the course of tumor 
growth.  
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Figure 25: Tumor regression is associated with prolonged predominance of 
L5178Y-specific IgG2a antibodies. 
Mice were implanted with 103 L5178Y cells on Day 0. Mice were bled over the 
course of tumor growth, and the relative abundance of tumor-specific IgG1 and 
IgG2a antibodies were assessed by western blot. A) The delay of tumor outgrowth 
is associated with a predominance of tumor-specific IgG2a antibodies. Subsequent 
progressive tumor growth correlates with the development of tumor-specific IgG1 
antibodies. B) Tumor regression is associated with a strong predominance of 
tumor-specific IgG2a antibodies is stable over time, while IgG1 antibodies to tumor 
antigens decrease over time. 
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4.9.1 Exploiting tumor-specific antibody subclasses to define immune 
correlates of protection, and implications for human disease  
There are obvious potential concerns when using tumor-specific antibodies 
rather than cytokine-secreting cells in defining immune correlates of protection. 
Tumor-specific antibody isotypes allow one to indirectly assess the Th1/Th2 nature 
of the systemic immune response. It is important to keep in mind that most 
subclasses of antibodies have a fairly long half life in the serum of mice. IgG, IgA, 
IgM, IgD and IgE subclasses have half lives of approximately 23, 5.5, 5, 2.8 and 2 
days respectively in the serum of mice (Benjamini and Sunshine 1996).   As such 
one must be aware that antibodies effectively give us an average view of the type 
of immunity present previously over the last few weeks. In contrast an analysis of 
cytokine producing cells at one time gives a snapshot picture. As most human 
cancers progress relatively slowly, such a hindrance may prove itself to be not 
important; however, it is more of an issue in the mouse models of cancer, which 
are selected to exhibit more rapid tumor regression/progression than would 
probably occur in a natural murine model of cancer.  
Most mouse models of cancer utilize isogenic tumors which induce rapid tumor 
growth. We observe, utilizing rapidly progressing tumors, a clear correlation 
between progression and the development of tumor-specific IgG1 antibodies. In 
mice suffering from a more protracted course of tumor growth, we observe the 
presence of a large amount of tumor-specific IgG2a antibodies. Such correlates are 
useful, but often with such mixed responses we are unable to confidently predict 
111 
 
whether the tumor will spontaneously resolve, or subsequently progress. Figure 25 
A depicts a situation in which the mouse suffers a rather protracted course of 
tumor growth. There is a period of roughly 10 days in which the animal is able to 
control the growth of the tumor. This transient control of tumor growth, as 
expected, correlates with a substantial amount of tumor-specific IgG2a antibodies; 
however, the tumor subsequently undergoes rapid tumor progression. Our 
western blotting protocol detected the development of tumor-specific IgG1 
antibodies, but we also detected the development of IgG1 antibodies in Figure 25 
A, where the tumor subsequently resolved. The critical difference appears to be 
that the IgG1 antibodies decrease over time, while tumor-specific IgG2a antibodies 
are sustained. Although the observations support our hypothesis we were unable 
to predict using western blots, at earlier time points, which of the tumors would 
ultimately resolve or progress. As most human cancers do not progress as rapidly, I 
believe very strongly that serial analysis of the Th1/Th2 nature of the anti-tumor 
immune response using this western blotting protocol may prove to be very useful 
in predicting the course of disease.  
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4.10 Common tumor antigens 
As discussed in the introduction, it is widely accepted that many tumor cells of 
different etiologies share common antigens against which the immune system 
mounts a response. In this regard, we assessed if we could detect antigens shared 
by both L5178Y and P815 using our western blotting strategy. As shown in Figure 
26 A, mice bearing a P815 tumor produce antibodies capable of recognizing L5178Y 
antigens which are not present in naïve sera. Conversely, similar cross-reactivity 
with P815 is seen with antibodies obtained from mice bearing a L5178Y tumor. To 
assess if such cross-reactivity is also present at the T cell level I assessed the ability 
of T cells from mice primed to either P815 or L5178Y tumors to produce cytokine 
when exposed to the other tumor in our ex-vivo ELISPOT assay. As shown in         
Figure 26 B, the cross-reactivity between the L5178Y and P815 tumors observed at 
the level of antibodies is not readily observed at the level of cytokine secretion. 
Such an observation is somewhat perplexing, and could perhaps be perceived as 
arguing against the possibility of a universal vaccine for the prevention of many 
common cancers, and may be responsible for the lack of cross-protection 
commonly observed between different tumor cell lines sharing common tumor-
associated antigens (Prehn and Main 1957; Ramarathinam, Sarma et al. 1995). It 
could also be argued that the shared antigens apparent by western blot may be 
mirrored at the level of cytokine secretion but that the relative abundance, the 
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efficiency of presentation, and immune dominance of these common tumor 
antigens may differ significantly among the two cell lines.  
There are grounds for optimism that a general strategy of vaccination 
against cancer may be realizable. Thierry Boon and his colleagues at the Ludwig 
Institute have discovered cross-reactive CTLs among patients sharing common HLA 
restriction elements (Skipper, Hendrickson et al. 1996). In light of these 
observations the prospect of a cancer vaccine remains a definite possibility.     
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Figure 26: Cross-reactivity of P815 and L5178Y tumor antigens as assessed by 
western blot is not complemented by cross-reactivity at the T cell level as 
assessed by the ELISPOT assay. 
A) Four mice primed to either P815 or L5178Y tumors generate antibodies that 
cross-react with tumor-associated antigens expressed by the other tumor, and two 
naïve mice were used as controls. Sera was used at a dilution of 1:75 B) P815-
primed mice were implanted with 105 P815 cells intradermally into their belly 14 
days prior to assay. L5178Y-primed mice were implanted with 103 L5178Y cells 
intradermally into their belly, and were challenged 4 months later with 106 L5178Y 
cells. An assessment of crossreactivity in the ELISPOT assay was assessed one 
month post-challenge. 
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4.11 Transfer of P815 resistance to naïve animals. 
We have examined the cell types required to transfer the protection we generated 
in P815 resistant mice to irradiated recipients. We can readily transfer protection 
using whole spleen cell preparations from mice rendered resistant. By depleting 
cell populations using midi MACS prior to transfer I have been able to demonstrate 
that protection is mediated by T cells, and that both CD4+ and CD8+ cells from 
primed mice are required to transfer this resistance (Figure 27). Although tumor-
specific CTLs are most likely responsible for the direct killing of P815 cells such an 
observation is not entirely unexpected as it has been demonstrated in other 
systems that specific CD4+ T cells are required to maintain effective CD8+ T cell 
memory (Janssen, Lemmens et al. 2003; Shedlock and Shen 2003; Sun and Bevan 
2003). 
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Figure 27: Characterization of the cell populations mediating protection against 
P815 tumor upon transfer into naïve, irradiated recipients. 
Donor mice were rendered resistant to P815 by priming with 105 P815 cells into 
their hind footpad 2 weeks prior to challenge with 2x106 P815 cells intradermally. 
Transfer was performed 2 months after challenge. Cells were nylon wool purified, 
and fractionated using midi-Macs (histogram inserts are a flow analysis of the cell 
populations transferred in each group). Recipient mice were given 850 rads of 
gamma-irradiation 24 hours prior to transfer. Recipient mice received an 
equivalent of 108 spleen cells from donor mice (iv), and were challenged 1 hour 
post-transfer with 106 P815 cells given intradermally into their belly. Tumor 
development was assessed. 
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4.12 Modulation of the Th2-type response associated with 
progressive P815 tumor growth utilizing neutralizing anti-
IL-4 antibodies as a therapeutic treatment 
If tumor-dependent IL-4 production by lymphocytes is indeed responsible for 
progression, one can examine whether immunotherapeutic strategies effective in 
other model systems where a mixed Th1/Th2-type immune response is associated 
with disease and a predominant Th1 response with resistance are effective in our 
tumor systems. Leishmaniasis is a parasitic disease caused by infection with a 
species of Leishmania ssp. The murine model of leishmaniasis has been 
exhaustively studied, and the correlates of protection are very well known. Mouse 
strains that mount a strong, stable Th1-type immune response to parasite antigens 
are able to contain the outgrowth of the parasite, while other strains that have a 
substantial Th2-type component to their immune response suffer from 
progressive/fatal disease. In this model, it has been recently shown that one can 
cure established stable lesions using neutralizing anti-IL-4 antibodies. This curing 
was shown to be due to a ‘switch’ of the immune response to the parasite away 
from the Th2 pole, towards a protective Th1-type immune response (Bretscher, 
Ismail et al. 2001; Uzonna and Bretscher 2001). In our experimental system, we 
strongly believe that the immune failure is very similar to that seen in 
Leishmaniasis. Consequently, we propose that anti-IL-4 therapy will effectively 
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switch the phenotypic anti-tumor immune response towards what we consider to 
be the protective Th1 pole, and cause the regression of an established tumor. 
 Mice implanted with 105 P815 cells intradermally into their belly were 
treated with neutralizing anti-IL-4 antibodies (11B11 clonotype) at various times 
and concentrations. The effect of such treatments on the survival of P815 bearing 
animals was assessed. As shown in Figure 28, our treated mice, on average, show 
prolonged survival as compared to control animals. As shown in Figures 29 and 30, 
this prolonged survival correlates with reduced rate of tumor growth, and an 
increase in the relative predominance of P815-specific IgG2a antibodies in their 
sera when compared with control animals. These observations suggest our 
treatment is having an effect on the phenotypic anti-tumor immune response 
which results in a prolongation of life.  
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Figure 28: Effect of anti-IL-4 treatment on the survival of P815 tumor bearing 
animals. 
Mice were implanted with 105 P815 cells intradermally on day 0. As indicated, 
treated mice were given different doses of neutralizing anti-IL-4 antibodies (11B11 
clonotype) at varying intervals. The effect of our treatment strategies were 
assessed as percent survival as compared to non-treated control animals. Survival 
curves are representative of five animals per group. 
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Figure 29: Relative abundance of P815-specific IgG1 and IgG2a antibodies in 
control animals. 
Mice were implanted with 105 P815 cells on day 0. Tumor development was 
assessed, and a Western blot to assess the relative predominance of P815-specific 
IgG1 and IgG2a antibodies was performed on day 14 of tumor growth at a serum 
dilution of 1:100. 
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Figure 30: Relative abundance of P815-specific IgG1 and IgG2a antibodies in P815 
bearing animals treated with anti-IL-4 antibodies. 
Mice were implanted with 105 P815 cells on day 0 and were given 0.3 mg of anti-IL-
4 antibodies (11B11 clonotype) on day 0 of tumor growth. Tumor development 
was assessed, and a Western blot to assess the relative predominance of P815-
specific IgG1 and IgG2a antibodies was performed on day 14 of tumor growth at a 
serum dilution of 1:100. 
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4.12.1 Potential concerns regarding anti-IL-4 treatment of the P815 tumor 
In our model system, P815 itself secretes IL-4 and for this reason we must 
appreciate the possibility that our anti-IL-4 treatments may be more complex than 
simply modulating the immune response towards the protective Th1 pole. This 
endogenous IL-4 production by a minority of P815 cells may potentially have many 
roles in-vivo with regards to promoting tumor progression. It is possible P815 
utilizes this IL-4 as a growth factor. By neutralizing its effects we may simply 
decrease the rate of P815 replication, creating an environment more favorable for 
the generation of tumor-specific Th1-type cells. In an attempt to partially address 
this possibility, we incubated P815 cells in-vitro with various concentrations of 
neutralizing anti-IL-4 antibodies and assessed if such treatment had an effect on 
tumor growth. As shown in Figure 31, it appears anti-IL-4 antibodies have very little 
effect on the rate of P815 growth, as compared to exposure to a control antibody 
(anti-CD4). One could also argue this IL-4 secretion may promote the development 
of a ‘pro-Th2-type’ tumor environment which may increase the tumorogenicity of 
P815. A third possibility is that the IL-4 produced has other biological roles not 
associated with immune modulation. There are reports in the literature that 
suggest IL-4 may be involved in the development of angiogenesis, thereby actively 
promoting the development and subsequent metastasis of the primary tumor 
(Fukushi, Morisaki et al. 1998). 
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Figure 31: Effect of anti-IL-4 and anti-CD4 antibodies on the rate of growth of 
P815 cells in-vitro:   
104 P815 cells were incubated with varying concentrations of neutralizing anti-IL-4 
antibodies (11B11) or anti-CD4 antibodies (GK1.5) for 24 hours in a 96 flat-
bottomed tissue culture plate. Cells were labeled with 0.5 µCi 3H Thymidine for the 
last 4 hours of culture before harvesting.  
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4.12.2 Modulation of the immune response against established, normally lethal, 
L5178Y tumor utilizing a low dose of gamma Irradiation to induce tumor 
regression 
Robert J. North has previously shown that a mouse, given 500 Rads of gamma-
irradiation six days after a normally lethal dose of the L5178Y, rejects the tumor 
(North 1984; North and Bursuker 1984; North 1986). As is shown in Figure 32, we 
have been able to reproduce this observation using 250 rads of whole-body 
gamma irradiation. Utilizing our EIA and western blotting protocol, we have 
demonstrated that the regression mediated by this treatment is associated with a 
switch in the type of immune response from a mixed Th1/Th2 type immune 
response to a predominant Th1 type response against tumor antigens as compared 
to the predominant Th2 in non-treated mice suffering from progressive L5178Y 
tumor growth. 
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Figure 32: Low-dose irradiation of L5178Y tumor-bearing animals induces 
immune-mediated tumor regression. This regression is associated with a switch 
in the phenotype of the anti-tumor immune response towards the Th1 pole, as 
inferred by IgG isotypes of anti-tumor antibody. 
Mice were implanted on Day 0 with 106 L5178Y tumor cells. Treated mice were 
given 250 Rads of whole-body gamma-irradiation on day 6 of tumor growth. The 
effect of the treatment was assessed by comparing the tumor growth in treated 
animals as compared to untreated controls. Mice were bled and the relative 
predominance of L5178Y-specific IgG2a and IgG1 antibodies were assessed by EIA. 
The observed tumor regression after low-doses of gamma-irradiated has been 
repeated in three independent experiments. The relative abundance of tumor-
specific IgG1 and IgG2a antibodies in induced tumor regression as compared to 
control animals has been repeated twice. 
128 
 
 
 
5 Discussion 
Despite decades of intensive research, the mechanism(s) responsible for immune 
failure against cancer remains poorly understood, and the literature reflects a view 
that this is a highly complex issue. The literature is composed of a spectrum of 
theories attempting to explain the inability of the immune system to control tumor 
growth. There are reports suggesting T cells are tolerized against tumor antigens 
(Bogen 1996; Staveley-O'Carroll, Sotomayor et al. 1998). However, such specific 
‘tolerance’ for tumor antigens may often be considered misleading, as it has been 
appreciated for more than a decade that spontaneous anti-tumor immune 
responses are often detectable in patients with progressively growing tumors 
(Ferradini, Mackensen et al. 1993; Mackensen, Ferradini et al. 1993; Zorn and 
Hercend 1999; Valmori, Dutoit et al. 2000; Griffioen, Borghi et al. 2001). Immune 
failure in the presence of a vigorous antigen-specific immune response can be a 
perplexing observation, but it is one not unique to tumors. In many microbial 
infections, clinical disease results not from a lack of specific immunity, but rather 
from the generation of a class of immunity ineffective at controlling microbial 
growth (Bretscher, Ismail et al. 2001). Observations made since the early 1960s 
have led immunologists, such as George Klein (Klein 1968), to  propose that strong 
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cell mediated immunity against tumor antigens is protective, while ineffective 
humoral responses are associated with tumor progression.  
Utilizing experimental systems whereby we could render mice resistant to 
normally lethal challenges of either the P815 or L5178Y tumor cell lines, both of 
which are syngeneic in DBA/2J mice, we developed techniques to assess the 
Th1/Th2 phenotype of the anti-tumor immune response in mice resisting or 
succumbing to the tumor. Using such systems, we attempted to ascertain if one 
could correlate resistance/progression with Th1 and Th2 immunity specific for 
tumor antigens. Such knowledge would allow for a better understanding of the 
mechanisms of immune failure, and allow one to develop strategies of prevention 
through vaccination and also immunotherapeutic strategies aimed at exploiting 
this endogenous anti-tumor immune response to improve cancer treatments.  
At present, there are no clinically useful and simple techniques to effectively 
and longitudinally assess the Th1/Th2 phenotype of a patient’s anti-tumor immune 
response. In this respect, it has been difficult to define any clear correlates of 
protection. We have developed ELISPOT, EIA and western blotting protocols which 
allow us to directly assess, or indirectly infer, the Th1/Th2 phenotype of an ongoing 
anti-tumor immune response. Exploiting these experimental tools, we have been 
able to define very clear immune correlates in our two tumor models. Of perhaps 
most interest, because of their practical simplicity, is our western blotting and EIA 
protocols which reveal our unique ability to longitudinally assess the Th1/Th2 
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phenotype of the anti-tumor immune response in the same animal as the tumor 
develops over time. Utilizing such techniques, we have been able to clearly 
demonstrate that cellular Th1 responses are associated with effective immunity, 
while the generation of mixed Th1/Th2 immunity against tumor antigens is 
associated with progressive tumor growth. The proposal that the immune 
correlates of resistance/tumor progression correlate with cell mediated (Th1) and 
humoral (mixed Th1/Th2) responses is not novel (Klein 1968); however, the 
majority of modern tumor immunologists support the idea that other causes of 
immune failure are more important.  
The in-vivo role of CD25+ T regulatory cells in dampening ongoing immune 
responses, in a purported effort to maintain self tolerance to peripheral self 
antigens, has become a very topical subject (Sakaguchi, Sakaguchi et al. 2001). 
Most current reports in the literature suggest that the generation of CD25+ T 
regulatory cells specific for tumor antigens act to inhibit the generation of effective 
anti-tumor immunity. Many of these conclusions are based on the  increased  
frequency of CD4+CD25+ T cells in patients with progressively growing tumors 
(Woo, Chu et al. 2001; Liyanage, Moore et al. 2002; Javia and Rosenberg 2003; 
Sasada, Kimura et al. 2003; Wolf, Wolf et al. 2003; Curiel, Coukos et al. 2004; 
Marshall, Christie et al. 2004). How or if such a correlation reflects the primary 
cause of immune failure in these patients remains to be determined. The present 
study does not directly assess a possible role of T regulatory cells; however, our 
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results suggest that a specific loss of immunity is not associated with tumor 
progression as would be expected if tumor-specific T regulatory cells were the 
primary factor in immune failure. We observe a phenotypic difference in the class 
of immunity generated against tumor antigens in mice rendered resistant to, as 
compared to normal mice suffering progressive tumor growth after being given a 
normally lethal dose of the syngeneic tumor. Based on our observations, one could 
surmise immune failure is not due to a specific loss of immunity, but rather the 
generation of ineffective immunity in response to tumor antigens. 
A decrease in the level of expression of tumor associated antigens is another 
mechanism leading to immune failure much reported and discussed in the 
literature (Biddison and Palmer 1977; Uyttenhove, Maryanski et al. 1983). It is very 
likely that such processes occur late during the course of tumor progression. Both 
the P815 and L5178Y tumor cell lines have been passaged in-vitro and in-vivo 
numerous times during the past roughly 60 years. One might hypothesize that both 
these cell lines are very adept at spontaneously changing their antigenic profile to 
evade the immune system. We have been able to consistently render mice 
resistant to tumors challenges, with both these cell lines, with challenges many 
fold above what is a semi-lethal dosage. These challenges with a high number of 
tumor cells (2x106), would favor the outgrowth of rare variants that have lost the 
expression of tumor associated antigens (Boon, Coulie et al. 2006). Furthermore, as 
shown in Figure 19, we observed one occurrence when mice, implanted with a 
132 
 
normally lethal dose of 105 P815 tumor cells, resulted in regression of the primary 
tumor. Subsequently, the tumor reemerged, and grew progressively at the site of 
implantation. It would be natural to suppose that such an occurrence followed a 
randomly generated tumor cell variant whose antigenic profile is no longer 
recognized by the immune system, so that it simply grew out from the quasispecies 
of the tumor cells still under immune control. We made two observations 
pertinent to evaluating this possibility utilizing our western-blotting protocol to 
assess the relative abundance of tumor-specific IgG1 and IgG2a antibodies. Firstly, 
the initial tumor regression correlated with a predominance of production of IgG2a 
antibodies, and as the tumor re-emerged, and progressively grew, we detected a 
switch to a predominant production of IgG1 antibodies against tumor antigens. 
Secondly, it appears upon a detailed examination of the western blots with sera 
taken at different times post tumor implantation, as though only the subclass of 
antibodies against the tumor antigens is changing, and not the antigens against 
which immunity is being generated. Such observations suggest there is no role for 
tumor variants affecting the class of immunity induced as a cause for tumor 
progression in this particular and unusual case. 
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5.1 Implications for the development of cancer vaccines 
The ever-expanding cancer immunome has identified a number of common 
tumor antigens against which patients commonly mount immune responses. Such 
observations have helped to fuel the enthusiasm for the potential development of 
a possible vaccine to prevent the development of many common cancers. One 
caveat in the development of such vaccines are reports that rendering mice 
resistant to one tumor does not cross protect against a different syngeneic tumor  
with which it shares common tumor antigens (Prehn and Main 1957; 
Ramarathinam, Sarma et al. 1995; Srivastava 1996). I observed the presence of 
tumor antigens shared between the P815 and L5178Y cell lines as assessed by 
western blot, and in a small preliminary experiment I wanted to assess if resistance 
to the L5178Y tumor could effectively vaccinate against a normally lethal challenge 
with the P815 tumor. As is shown in Figures 33, both control mice suffered rapid 
tumor growth. Such tumor growth was associated with predominant IgG1 
responses generated against the P815 tumor antigens. Interestingly, we observe 
no cross-reactive antibodies recognizing L5178Y antigens. I observed a much 
slower rate of P815 tumor growth in both mice vaccinated three months prior with 
103 L5178Y tumor cells (Figure 34) as compared to the control mice. One 
vaccinated mouse was able to resolve, while the other had an uncharacteristic 
unprogressive tumor growth for three weeks, but ultimately suffered from 
progressive growth. One is able to clearly observe a much higher IgG2a:IgG1 ratio 
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against tumor antigens in the mouse which successfully contained the P815 
challenge, and a much lower ratio in the mouse that succumbed from tumor 
growth.   
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Figure 33: Progressive P815 tumor growth is associated with the predominance 
of IgG1 antibodies specific for P815 antigens. 
Mice were implanted with 105 P815 cells intradermally into their belly on Day 0. Rate of 
tumor growth was monitored, and Sera was collected weekly to assess the relative 
abundance of tumor-specific IgG1 and IgG2a antibodies by western blot using either P815 
or L5178Y as antigen.   
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Figure 34: Effect of L5178Y vaccination on the growth of a normally lethal 
challenge with the P815 tumor 
Mice were vaccinated with 103 L5178Y cells intradermally into their belly 3 months prior to 
challenge with 105 P815 cells intradermally into their belly on Day 0. Rate of P815 tumor 
growth was monitored, and sera was collected weekly to assess the relative abundance of 
tumor-specific IgG1 and IgG2a antibodies by western blot using either P815 or L5178Y as 
antigen.   
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Perhaps and most interestingly, by assessing the ratios of tumor-specific IgG1 and 
IgG2a antibodies over the course of the experiment, one could have tentatively  
predicted which of the two mice was going to contain, or suffer progressive tumor 
growth, at times where both had roughly the same size tumor. I recognize that this 
is a preliminary experiment involving very few animals, and only present it here as 
an interesting observation showing cross-protection between the P815 and L5178Y 
tumors in contrast to a report by RJ North and colleagues who observed no such 
cross reaction (Dye and North 1984).   Such cross-protection between tumor cell 
lines, which share common antigens, provides hope that vaccines against several 
common antigens may be capable of preventing much cancer. As discussed in the 
previous section, it should be kept in mind that for such vaccines to be effective, 
they must induce strong, Th1 responses against tumor antigens (see Figure 35 
bottom panel, (Bretscher, Hamilton et al. 2002).   
5.2 Implications for cancer therapy 
R.J. North’s classical studies on the kinetic development of concomitant 
immunity, and its subsequent decline associated with the generation of tumor-
specific suppressor CD4+ T cells, demonstrates a highly dynamic aspect of the anti-
tumor immune response (North and Bursuker 1984). One must appreciate that the 
types of immunotherapeutic strategies that are most effective at treating cancers 
may be different depending on the phenotype of the endogenous anti-tumor 
immune response at the time of treatment. As such, the ability to assess the 
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nature of the anti-tumor immune response is critical for the development of 
effective, clinically relevant, immunotherapeutic strategies. Utilizing western blots, 
we have developed a uniquely simple methodology to assess the Th1/Th2 nature 
of ongoing anti-tumor immune responses in mice, and place them within the 
conceptual framework of concomitant immunity described by R.J. North.  
The relative prevalence of specific antibody belonging to different IgG 
subclasses, has proven itself useful as a measure of the Th1/Th2 nature of the 
immunity in human disease. In their studies on visceral leishmaniasis, Bretscher 
and colleagues demonstrated one could easily distinguish patients from healthy 
contacts based upon the relative abundance of parasite-specific antibody 
subclasses. Interestingly, one healthy contact had an antibody profile similar to 
patients. It was noted that this individual subsequently developed disease (Hailu, 
Menon et al. 2001). Observations such as these demonstrate that such techniques 
are not only useful in simply defining immune correlates, but can also be 
diagnostic. 
 In the case of our tumor models, one could explore the utilization of a similar 
strategy that examines how the ratio of tumor-specific IgG2:IgG1 antibodies 
develop over time. I hypothesize that disease progression could be predicted if this 
ratio decreases rapidly over time. In situations where the ratio remains high, or 
increases over time, I would predict a favorable outcome. In contrast, ratios when 
low or where they decrease rapidly, one might be able to predict exacerbation of 
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tumor growth prior to the development of overt symptoms. If such a technique is 
proved useful, it would represent a very powerful diagnostic tool in the fight 
against cancer.  
Assuming our observed correlates of regression/progression are mirrored in 
humans, one can envisage the potential for developing immunotherapeutic 
strategies to treat cancer by utilizing interventions that switch established, mixed 
Th1/Th2 responses towards a protective, Th1 response against the tumor. It is a 
somewhat underappreciated that established Th1/Th2 responses in chronic 
infections are not cast in stone. Through simple procedures, one can effectively 
modulate the immune response towards a Th1 mode (Hailu, Menon et al. 2001; 
Uzonna and Bretscher 2001). Such treatments, when optimized, should be capable 
of switching the response towards a Th1 mode, leading to increased effectiveness 
of current anti-tumor treatment strategies. 
Exploiting an experimental system developed by Robert North (North 1986), 
we have been able to induce regression of an established, progressively growing 
L5178Y tumor, using low doses of gamma-irradiation.  We have been able to 
demonstrate that such regression is associated with the development of a high 
ratio of tumor-specific IgG2a to IgG1 antibodies, while in untreated control mice 
we observe a decreasing ratio as the tumor progresses. Some may interpret the 
low-dose irradiation, and subsequent tumor regression, as preferentially depleting 
tumor-specific CD4+ CD25+ regulatory T cells (Ghiringhelli, Larmonier et al. 2004; 
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Turk, Guevara-Patino et al. 2004). I did not assess the direct effects of these low 
doses of irradiation on the development of T regulatory cells. It is possible such low 
dose irradiation depletes T regulatory cells to allow for the generation of 
protective immunity; however, as discussed in the introduction, I personally do not 
favor such an interpretation. It has been reported that T regulatory cells are 
capable of directly suppressing B cell activation (Lim, Hillsamer et al. 2005). In mice 
suffering from a progressively growing L5178Y tumor, we never observe a lack, or 
decrease, in the anti-tumor immune response as assessed by production of 
antibody. I have consistently observed an increase in the Th2-component of the 
anti-tumor immune response; furthermore, there is no evidence in the literature 
suggesting regulatory T cells have any such effect on the switching of antibody 
subclasses.  
Contemporary chemotherapeutic agents are, in general, not appreciated for 
their potential effects on the immune system. It is often assumed that the 
powerful anti-proliferative properties of traditional chemotherapeutic agents act 
primarily upon the rapidly proliferating tumor cells. Often it is not appreciated that 
such drugs also have a profound impact upon the concurrent anti-tumor immune 
response. It has been shown that such treatments, for example the administration 
of cyclophosphamide, when utilized appropriately, are capable of enhancing 
delayed type hypersensitivity at the expense of humoral immunity (Turk, Parker et 
al. 1972; Lagrange, Mackaness et al. 1974; Mitsuoka, Baba et al. 1976; Goto, 
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Mitsuoka et al. 1981). These studies for the most part involve non-replicating 
antigens such as xenogenic red blood cells. The effect of such agents cannot in this 
case be indirect, acting on the replicating antigen and thus indirectly reducing its 
effective ‘dose’. Rather, the anti-mitotic agents in these cases are more likely to act 
on replicating cells of the immune system. The effects of these agents are 
comprehensible in the context of a cooperative model of T cell activation. In such a 
model, T cells specific for a given antigen cooperate not only to induce the 
generation of effector cells, but also the ‘strength’ of antigen-mediated CD4 T cell 
cooperation  determines the Th1/Th2 phenotype of the effector T cells generated. 
Limiting cooperation either by limiting antigen concentration or numbers of 
specific CD4+ T cells has been shown to preferentially generate Th1 cells. 
Conversely, by increasing either antigen concentration or numbers of specific CD4+ 
T cells one can preferentially generate Th2 cells (Bretscher, Ismail et al. 2001; 
Ismail and Bretscher 2001). Traditional anti-cancer treatments that inhibit division 
of lymphocytes, such as administration of cyclophosphamide, or irradiation, have 
the potential, if given at the correct level, to modulate mixed Th1/Th2 responses to 
a Th1 mode. In this respect, being able to assess the effects of chemotherapeutic 
agents on the endogenous anti-tumor immune response may allow clinicians to 
tailor their treatment strategies to facilitate the promotion of protective Th1 
responses at the expense of ineffective, Th2 immune responses specific for tumor 
antigens. 
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This dissertation forms a foundation for many potential future studies. An 
obvious route of investigation is to see if one can detect tumor-specific antibodies 
in cancer patients, and determine if one can correlate the relative predominance of 
tumor-specific Ig subclasses with disease progression and/or response to 
treatment. Our simple western blotting protocol would allow us to longitudinally 
assess the effects that traditional cancer therapies have on the Th1/Th2 nature of 
the anti-tumor immune response. Such information may allow one to tailor the 
cancer treatment regimen to fully exploit the endogenous anti-tumor immune 
response. Such experimental data may prove very significant in helping to improve 
the effectiveness of current strategies of cancer treatment. 
The immune correlates presented within this thesis may also allow the 
development of effective cancer immunotherapies.  The direct modulation of 
ongoing anti-P815 immune responses, as presented in this thesis, is somewhat 
inconclusive. In some anti-IL-4 treated mice we have observed a decreased rate of 
tumor growth, as compared to control animals. This decrease in the rate of growth 
often correlates with an increase in the predominance of P815-specific IgG2a 
antibodies. Such observations suggests one can modulate ongoing anti-tumor 
immune responses; however, it is likely P815’s inherent aggressiveness does not 
lend itself well to being a model for immunotherapeutic strategies, and most likely 
is not representative of most human cancers. The immune response generated 
against L5178Y has shown itself to be easily modulated by gamma-irradiation to 
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induce immune-mediated clearance of the tumor. This suggests it is an ideal 
system in which to assess the utility of immunotherapeutic strategies to induce 
regression of an established tumor. Such treatments could include the above-
mentioned neutralizing anti-IL-4 treatment, and partial depletion of CD4+ T cells, 
both maneuvers having been shown effective at modulating established mixed 
Th1/Th2 immune responses towards the Th1 pole (Uzonna and Bretscher 2001).  
Many current cancer immunotherapeutic strategies, such as those developed 
by Rosenberg and colleagues, involve the ex-vivo expansion of tumor-reactive 
lymphocytes (Dudley and Rosenberg 2003).  Such strategies have had some success 
at inducing tumor regression (Rosenberg, Yannelli et al. 1994); however, as was 
reported by RJ North (North, Dye et al. 1982), often treatment also requires 
reduction in the number of T cells in the patient to improve efficacy (Dudley, 
Wunderlich et al. 2005). Based upon the observations discussed within this thesis, I 
would argue that such procedures are not effective by causing the simple inflation 
of effector cells, but rather the intervention to be effective must act to switch the 
phenotype of the anti-tumor immune response from an ineffective Th2 or mixed 
Th1/Th2, towards an effective, Th1 mode. One may be able to greatly improve the 
efficacy of such immunotherapeutic strategies.  
Observations made by Bretscher and colleagues have demonstrated that it is 
possible to switch a humoral to a strong cellular immune response in-vitro. It was 
observed that such a switch was associated with the generation of antigen-specific 
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CD8+ T cells able to inhibit antibody response in an antigen-specific manner 
(Tuttosi and Bretscher 1992). The ability to effectively assess the Th1/Th2 nature of 
the anti-tumor immune response could allow one to develop in-vitro strategies to 
promote the expansion of cells capable of successfully inducing immune clearance 
of established tumors. 
The development of the cancer immunome has really allowed one to envisage 
how vaccines might be developed that prevent the outgrowth of many common 
cancers. Our results suggest that immunity to such antigens is not enough to 
induce protection against cancers. To induce protective anti-tumor immunity, one 
must ensure the development of the correct type of immune response. Previous 
work in this laboratory has demonstrated mechanisms by which one can 
consistently induce Th1 immune responses in genetically diverse mice (Menon and 
Bretscher 1996; Menon and Bretscher 1998). By exploiting these systems, one 
could potentially devise vaccination strategies by which one could induce 
protective Th1 immunity against tumor associated antigens in a diverse population 
(Menon and Bretscher 1998; Power, Wei et al. 1998; Bretscher, Ismail et al. 2001). 
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5.3 Concluding Remarks 
It seems to me that there has been a loss of optimism over the past few 
decades in the field of tumor immunology. By approaching the field of tumor 
immunology, from a particular perspective that we thought might be too simplistic, 
we have been able to utilize very simple techniques to define correlates of 
protection. We do not know how generalized our observations might be. 
Nonetheless, we feel such simple techniques have the potential to reshape current 
thinking, leading to improvements in traditional cancer treatments, and allow for 
the development of new cancer immunotherapeutic and vaccination strategies to 
treat and perhaps prevent the frank occurrence of many common cancers. 
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